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ABSTRACT 
Background  
Emergency contraception (EC) offers a last chance to prevent an unwanted pregnancy after 
unprotected sexual intercourse (UPSI) but before pregnancy occurs, for example after contraceptive 
failure, non-use of contraception or after rape. Progesterone receptor modulators (PRMs) exert their 
effect through acting as partial antagonists and partial agonists of the progesterone receptor (PR) and 
have proven effective for EC in low doses by postponing or inhibiting ovulation if it was taken pre-
ovulatory in the menstrual cycle. They further affect the endometrium in a dose-dependent manner 
and high doses inhibit endometrial development and affect embryo implantation. There are concerns 
regarding thickening of the endometrium and the specific PRM associated endometrial changes 
(PAEC) that long-term PRM treatment can cause. However, there is no knowledge of the underlying 
molecular basis of this condition. It is further not known if the PRM ulipristal acetate (UPA) used as 
EC could interfere with the contraceptive effect of a regular combined oral contraceptive pill (COCP) 
initiated immediately after UPA intake or if UPA in the dose used for EC affects endometrial 
receptivity and embryo implantation. Low doses of mifepristone have not been explored regarding its 
effect on the embryo implantation process. 
Aim  
The overall aim of this thesis was to explore the effects of PRMs mifepristone and UPA when used for 
EC and further develop them for contraceptive purposes and to provide women with evidence-based 
information and advice on mechanisms of action of PRMs. The specific objectives were to investigate 
the clinical implications of their effects on ovaries and endometrium. This included short-term effects 
on endometrial receptivity and the embryo implantation process as well as long-term endometrial 
effects and further possible interaction with regular hormonal contraception.  
Materials, Methods and Results  
Study I was a multicenter, double-blind, randomized, placebo-controlled trial in which 76 healthy 
female volunteers between the ages of 18 and 35 with regular menstrual cycles were randomized to 
receive either 30 mg UPA or placebo at mid-cycle when the dominant ovarian follicle was ≥ 13 mm, 
followed by intake of a common COCP during 21 subsequent days. Hormonal measurements and 
transvaginal ultrasonography were performed regularly to assess ovarian activity. Ovarian quiescence 
was achieved after 7 days of COCP intake for most women, however in some women it took up to 14 
days, irrespective of UPA administration. The proportion of women who ovulated in the study was 
approximately 30%, similar in both groups, which could be explained by follicle size at inclusion.  
Study II and III were exploratory studies on the human embryo implantation process and 
endometrial receptivity markers after treatment with UPA in an EC dose (Study II) and mifepristone 
in two different low concentrations (Study III) using a 3D human endometrial in vitro cell culture 
model. Endometrium was collected from proven fertile volunteers with regular menstrual cycles at 
cycle day LH+4 and endometrial stromal and epithelial cells were isolated and 3D constructs 
developed. Viable human blastocyst stage embryos, donated from couples that underwent IVF, were 
randomly allocated to the different treatment groups (UPA 200ng/ml ≈0.4µM, mifepristone 0.05µM, 
mifepristone 0.5µM and control). When the epithelial cells had grown into a confluent layer, the 
embryos were placed on top of the culture and further co-cultured for 5 days. The embryo attachment 
rates in different groups were: 5/10 in UPA, 4/10 in mifepristone 0.05µM, 0/8 in mifepristone 0.5µM 
and 7/10 in the control group. Some of the known endometrial receptivity markers in Study II were 
altered in the UPA group but most were unaffected. On the other hand, most of the receptivity 
markers examined in Study III were altered, with both the concentrations of mifepristone. However, 
they exerted functionally different effects on embryo implantation in a dose-dependent manner.  
Study IV was an exploratory study in which endometrial samples had been collected from fourteen 
healthy, pre-menopausal women, randomized to receive mifepristone during 3 months prior to 
surgical intervention of uterine leiomyoma in a previous placebo controlled trial. Endometrial biopsies 
obtained during surgery after the treatment period were assessed for the occurrence of PAEC and 
further explored regarding gene and protein expression in endometrium with PAEC compared to non-
PAEC after mifepristone treatment. Methods used included histological evaluation, microarray 
analysis, Ingenuity Pathway Analysis, real-time PCR, protein extraction and mass spectrometry. Three 
genes relevant to functions and diseases of the uterus were upregulated in endometrium with PAEC; 
ADAM12, THY1 and TN-C and 25 different proteins were upregulated and five downregulated in 
endometrium with PAEC. 
Conclusion  
UPA-EC does not interfere with the ability of a COCP to induce ovarian quiescence when treatment is 
quickstarted immediately after EC intake and the treatment is safe and tolerable. Further, UPA in a 
concentration corresponding to EC dose does not inhibit embryo implantation, nor does a very low 
mifepristone concentration of 0.05µM, whereas mifepristone in a concentration of 0.5µM effectively 
inhibited attachment of the embryo to the endometrial construct in vitro. The specific morphological 
features of PAEC displayed after 3 months of mifepristone treatment may be explained by the altered 
expression of molecules affecting tissue architecture and extracellular matrix, however these 
molecules were not involved in endometrial cancer-signaling pathways based on IPA knowledge base. 
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  1 
1 INTRODUCTION AND RATIONALE 
 
Since the ovarian steroid hormone progesterone is essential for human reproduction, 
progesterone receptor modulators (PRMs), with their intrinsic antifertility properties, have 
been explored and developed for contraceptive purposes. PRMs are currently in use for 
emergency contraception (EC), as daily treatment of symptomatic uterine leiomyoma, in 
combination with a prostaglandin analogue for termination of early pregnancy, for cervical 
ripening prior to surgical abortion and induction of labor at intrauterine fetal death (IUFD).  
Emergency contraception provides women with a last chance to prevent an unwanted 
pregnancy following unprotected sexual intercourse (UPSI), contraceptive failure or after 
rape. The most recently developed dedicated EC method is the selective PRM ulipristal 
acetate (UPA) in a low single oral dose, taken within 120 hours after the event of an UPSI. 
The mechanism of action of UPA when given pre-ovulatory in the menstrual cycle is to 
inhibit or postpone ovulation beyond the life span of sperm, consequently preventing 
pregnancy. UPA has proven to be more effective than levonorgestrel (LNG), the other 
dedicated hormonal EC pill (ECP) on the market, which has raised a debate whether or not it 
also exerts postfertilizing effects. In addition, UPA is similar in molecular structure to the 
PRM mifepristone, which in a high single dose in combination with misoprostol is an 
established method for induced medical abortion.  
Mifepristone in a low dose can be used as EC and together with UPA further has potential for 
development as regular estrogen-free contraception. However, implications of the frequently 
occurring PRM associated endometrial changes, PAEC, as seen during long-term leiomyoma 
treatment, are not known.  
The cellular and molecular events that mediate human embryo implantation process are 
largely unknown and there are few in vitro models for studying early events in human 
pregnancies and regulating factors. Endometrial studies are of importance to identify 
biological markers of endometrial receptivity, which can be used for development of more 
effective EC methods and safe and effective long-term contraception. 
When the research project started there were no data available on interaction between UPA-
EC and regular hormonal contraceptives. Since UPA binds to the progesterone receptor (PR), 
it could theoretically interfere with progestogen-containing products and the manufacturers 
current advice to women was therefore to use barrier methods or abstinence after UPA intake 
until the next menses. However, effective regular contraception should preferably be initiated 
or continued as soon as possible after EC use in order to ensure ongoing contraception and 
prevent a future unintended pregnancy, also as further acts of UPSI in the same cycle as EC 
intake increases the risk of pregnancy.  
 
 2 
The rationale for this project was the urgent need of data on the potential interaction between 
UPA-EC and a common combined oral contraceptive pill (COCP) when practicing 
‘quickstart’ of a regular contraception after UPA intake, to enable evidence-based advice to 
women regarding additional contraceptive measures needed to prevent pregnancy before they 
can rely on their routine contraception. Likewise, it felt urgent to determine mechanisms of 
action of PRMs when used for EC, with regards to effects on the endometrium and the 
embryo implantation process. Women around the world are frequently withheld access to the 
most effective products due to beliefs of postfertilizing effects and a large number of women 
are thereby put at risk of becoming unwanted pregnant and further at risk of maternal 
morbidity and mortality. It is of great importance to provide women with evidence-based 
information in regards to UPA-EC effect on embryo implantation. 
Knowledge about endometrial receptivity can apart from the development of novel agents for 
contraceptive purposes be used to understand and improve fertility for women who suffer 
from infertility. For safety reasons however, before developing PRMs as ongoing 
contraception or extending leiomyoma treatment, implications of PAEC need to be 
elucidated.  
The overall purpose with the studies was to add more understanding to the field of female 
reproductive physiology in relation to the mechanisms of action of PRMs when used for 
prevention of unintended pregnancies and ultimately contribute to women’s reproductive 
health and wellbeing. 
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2 BACKGROUND 
2.1 UNINTENDED PREGNANCIES AND UNSAFE ABORTIONS 
Approximately 45% of pregnancies were unintended in the US in 2011 [1]. This rate is 
similar to the 85 million unintended pregnancies out of estimated 213 million pregnancies 
that occurred worldwide in 2012 [2]. An incomprehensibly large number of women and girls 
suffer and die everyday from preventable conditions related to reproduction around the world. 
Unsafe abortions of unwanted pregnancies substantially contribute to maternal morbidity and 
mortality and further almost exclusively take place in the developing world [3, 4]. 
 
Figure 1.  World map 2012 Unintended pregnancies per 1,000 women aged 15-44  
Modified from Sedgh et al 2014, Studies in Family Planning 2014; 45(3): 301-314 
 
Based on estimates for 2008, around 22 million unsafe abortions occurred worldwide, which 
was nearly half of all induced abortions that year [5]. More recent calculations on abortion 
incidence and levels worldwide estimated that 56 million abortions took place globally each 
year between 2010 and 2014 and thus one in four pregnancies ended in an induced abortion 
[6]. Sedgh et al further established that although abortion rates have declined significantly in 
the developed world since 1990, they in contrast increased in the developing world and 
concluded that increased investments and expanded access to family planning programs are 
needed [6]. In addition, it is important to consider the rapidly growing population and 
increasing number of women of reproductive age in areas where women are less able to 
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control their fertility due to restrictive abortion laws or where easy access to safe procedures 
is lacking. Irrespective of existing laws and religious beliefs, women will continue to have the 
need for abortions and to seek assistance for it. An abortion performed in accordance with 
recommended WHO guidelines is a very safe medical procedure with few complications. It is 
considered unsafe however if performed by a person lacking the appropriate skills or in a 
setting not conforming to minimal medical standards, or both [5]. Other risks, such as the 
legal status and social context are moreover important factors or barriers to consider when 
assessing safety of abortions. One aspect of safety regards the increasing informal use of 
misoprostol for medical induction of abortions, which could be performed safely even in 
settings where abortion is illegal. The concept of safety in this matter is complex and has 
lately been discussed and suggested to be assessed as a risk continuum rather instead of a 
binary measure [7]. In 2012, an estimated 7 million women were treated for abortion related 
complications in health facilities in the developing countries, however the total morbidity 
burden for these complications in the population naturally being much greater [8]. There is an 
uneven distribution of pregnancy-related complications globally and 62% of deaths related to 
unsafe abortions occur in Africa [5]. 
Unintended pregnancy is a very common condition that can be life threatening and in 
addition imply health consequences that are not fatal, thus constituting a public health 
problem. Most complications from unsafe abortions are unnecessary and avoidable with 
increased access to safe abortion and post-abortion care. Moreover and most important, 
unintended pregnancies are preventable with access to safe and effective contraception. 
 
Figure 2. Percentage of women aged 15-49 (married or in a union) using any method of contraception 2015 
Modified from United Nations, Department of Economic and Social Affairs, Population Division (2015a) 
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2.2 UNMET CONTRACEPTIVE NEED 
Despite an overall increase in contraceptive use globally, the unmet need for contraception 
remains high and the demand is increasing due to growing populations and simultaneous 
increased preference to have smaller families. The unmet need for contraception most often 
refers to sexually active women of reproductive age who do not wish to become pregnant but 
who are not using a modern method of contraception [9]. However, most calculations of the 
unmet need for contraception only consider women who are reported to be married or in a 
union, thus not taking into account all the other sexually active women in the world, why the 
figures arguably would be underestimated [2]. On the other hand, the results from studies 
estimating the unmet contraceptive need in all women might be less reliable and more 
difficult to compare from time to time or in between countries, due to difficulties in many 
places to obtain information about unmarried or adolescent women’s engagement in sexual 
activities and thereby need for contraception.  
Estimates for 2014 from the Guttmacher Institute in New York, US, showed that as many as 
225 million women globally have an unmet need for modern contraception and that if the 
unmet contraceptive needs were to be fulfilled, an estimated 52 million unintended 
pregnancies and 24 million abortions would have been averted that year [10]. In addition, 
Ahmed et al earlier concluded that maternal mortality would be reduced by nearly a third if 
the unmet contraceptive need worldwide would be fulfilled [11]. 
There are unacceptable differences in reproductive health and inequalities in provision and 
access to SRH services between developing and developed countries as well as variations 
within the countries. The need for contraception is greatest in the developing countries where 
also nearly all unsafe abortions take place and the risks of maternal morbidity and mortality 
are highest. The most vulnerable women are disproportionally affected, consequently being 
the poorest and the youngest [12]. Considering the 23 million adolescent women with an 
unmet need for contraception worldwide [13] and whose lives and wellbeing are at risk, it is 
crucial to improve SRH services where needed to secure their reproductive future. This 
includes ensuring access to safe abortion services as well as providing information about and 
improve uptake of modern, effective and affordable contraceptive methods. It is further of 
great importance to understand barriers to contraceptive use and women’s reasons for non-
use where contraception is available in order to improve quality of interventional programs. 
In the campaign Safe Motherhood Initiative from 1987, family planning was identified as one 
of four cornerstones to reduce maternal mortality. Later on in 1994, at another landmark 
event of sexual and reproductive health and rights (SRHR); the International Conference on 
Population and Development (ICPD), not only the definition of SRHR was articulated but 
further the importance to advance these rights, which included a consensus of achieving 
universal access to SRH services by 2015. Building further on the United Nations (UN) 
declaration of health-related Millenium Development Goals (MDG) from 2000, the 
committment of ensuring universal access to SRH services was once again announced, 
together with the agenda to end preventable newborn, child and maternal deaths at the more 
 6 
recent 2030 Agenda for Sustainable Development in 2015 [14]. Since socioeconomic 
inequities including low educational level and living in rural areas are associated with 
increased risk of experiencing complications following unintended pregnancies [12] these 
global initiatives also address poverty and empowerment of women as essential targets for 
improving reproductive health. 
The freedom to choose if and when to become pregnant in order to achieve their fertility 
goals is not only beneficial for the woman and her autonomy to control spacing, timing and 
number of children, but likewise for her family and society. Positive correlations have also 
been demonstrated in high-income countries. In a Swedish study investigating the effect of 
subsidizing oral contraceptives, it was concluded that increased access to contraception 
results in a significantly higher socio-economic status later in life for the women and further 
in better health and performance in school for their offspring [15]. Thus, assuring the 
fundamental human rights of SRH also holds public health benefits for women and men. 
 
2.3 EMERGENCY CONTRACEPTION 
Emergency contraception (EC) is a postcoital contraceptive method that provides women 
with a last chance to avoid an unwanted pregnancy after the event of unprotected sexual 
intercourse (UPSI) but before pregnancy occurs [16], for example in situations of non-use of 
contraception or several missed pills, contraceptive failure such as condom breakage or after 
rape. 
EC is often referred to as the “the morning after pill” in lay language. This is however 
somewhat misleading, both regarding the time window of effect of treatment and the route of 
administration. The current available categories of EC are intake of an oral hormonal EC-pill 
(ECP) as soon as possible within 3-5 days after UPSI or insertion of a copper-intrauterine 
device (Cu-IUD) within 5 days. A substantial percentage of expected pregnancies can be 
prevented by EC, reported between 57-99% depending on method and when used in the 
menstrual cycle [17-19]. Mechanisms of action of EC include preventing fertilization of the 
egg cell or preventing implantation of the fertilized egg in the uterus.  
The increase in EC availability has been quite dramatic globally during the past two decades 
with development of new safe and effective dedicated ECPs and increased general 
knowledge of the method. Currently, EC is available in over 140 countries, among which in 
more than 60 possible to purchase over the counter (OTC). The term “dedicated ECP” refers 
to medication specially labeled and packaged for use as EC. Regular COCP on the contrary 
are not specifically developed for this purpose, although possible too use as EC if no other 
option is available. Despite a range of regular effective contraceptives available on the 
market, the unmet contraceptive need is large, where EC access and use might provide a 
bridge to start with a regular contraceptive method. Further, women who use regular 
contraception will in addition undoubtedly at times have a need for EC as inconsistent use or 
failure to use a contraceptive method correctly frequently occurs.  
  7 
Due to difficulty in assessing the time of ovulation, EC treatment is recommended for women 
who do not wish to become pregnant after an UPSI regardless of when in the menstrual cycle 
it took place. Seemingly, the fertile window would be rather easy to predict for women with 
regular menstrual cycles as this period occurs in accordance with the time of ovulation. 
However, ovulation has shown to be highly variable and sporadically occurring outside the 
expected time, also for women stating that their cycles are regular, which in addition thus 
results in a range of unpredictable fertile days [20]. Moreover, the menstrual cycle day 
reported by women often does not coincide with objective hormonal measures [21] and UPSI 
outside the fertile period may also result in pregnancy [20].  
Studies have further suggested that sexual intercourse and ovulation do not occur 
independently. The reason for this is the observation that even women who do not try to 
conceive are more likely to have sexual intercourse during the fertile days in the cycle with 
reported increasing frequency during the follicular phase up to a peak near ovulation and 
thereafter a rather sharp decrease [22, 23]. Several hypotheses regarding the reason for this 
pattern have been proposed, including cyclic increase in the woman’s libido and sexual 
attractiveness, or even that ovulation is accelerated or triggered by sexual intercourse as seen 
in certain other species [23]. Altogether, EC should be offered to women who request it since 
it is not possible to objectively determine if the UPSI took place during the woman’s fertile 
period and since the risk for pregnancy when a woman seeks EC is not negligible. 
EC is further a critical treatment in post-rape care that substantially could reduce pregnancy 
following rape [24] and is recommended by the WHO to all women in all settings [25]. 
Although EC is important after sexual violence and should routinely be provided rape victims 
to prevent pregnancy following rape, provision of EC varies substantially worldwide. Many 
guidelines do not include offering EC to rape-survivors despite that pregnancies after rape are 
not uncommon and further risks additional traumatic consequences for the woman 
(http://www.cecinfo.org) (accessed April 2017). In addition, EC access is crucial in crisis-
affected regions where wars, conflicts and natural disasters put millions of displaced girls and 
women at risk of sexual exploitation, rape and other forms of gender-based violence (GBV). 
Women in conflict settings most often do not have access to basic SRH services, including 
methods for prevention or treatment of unwanted pregnancies, nor to undergo a safe 
pregnancy and childbirth. These conditions underscore the importance of EC availability and 
for increased awareness and knowledge among health workers in refugee settings. Further, 
counseling and access to EC is also recommended in response to epidemic challenges such as 
the Zika virus [25]. 
Undoubtedly, safe and effective contraception, including EC, is essential in preventive 
medicine. Consequently, the World Health Organization (WHO) endorses EC and has it 
included on the Model Essential Medicines List (EML) [26]. EC is included on the EML in 
60 countries in the world (http://www.cecinfo.org) (accessed April 2017). 
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2.4 HISTORICAL PERSPECTIVES ON EC 
2.4.1 Emergency Contraception in ancient times 
Various methods to prevent pregnancy with instructions on how to use medicinal plants with 
antifertility properties have been described since the beginning of recorded history. From 
Egyptian papyrus 1850 BC and classical texts from East Asia and India through ancient 
Greek and Roman documents, methods for abortion as well as contraception including 
methods for postcoital contraception are reported. 
The Greek physician Soranus of Ephesus practiced gynecology in Alexandria and Rome 
approximately AD 98-138 and was the author of several medical textbooks. In his 4 volume 
textbook on Gynecology he describes a postcoital method to prevent pregnancy: “ … one 
must consequently be aware of having sexual intercourse at those periods which we said 
were suitable for conception. And during the sexual act, at the critical moment of coitus when 
the man is about to discharge the seed, the woman must hold her breath and draw herself 
away a little, so that the seed may not be hurled too deep into the cavity of the uterus. And 
getting up immediately and squatting down, she should induce sneezing and carefully wipe 
the vagina all round; she might even drink something cold. It also aids in preventing 
conception to smear the orifice of the uterus all over before with old olive oil or honey or 
cedar resin or juice of the balsam tree, alone or together with white lead; or with a moist 
cerate containing myrtle oil and white lead…” [27]. 
Although most recommendations are not efficacious, the antifertility activity of several 
medicinal products mentioned in ancient literature has been further explored in modern time 
and a few are undergoing clinical trials after reassuring animal studies. One of the plants used 
for abortion and contraception since ancient times, in addition described for postcoital use, is 
the wild carrot Queen Anne’s Lace (Daucus carota), which still is supposedly used 
traditionally in India. Extract from its seeds is in fact also possible to purchase nowadays via 
mail order, where advertised as “a natural contraceptive” with instructions to use daily from 
one day prior to ovulation and for one week ahead to avoid implantation after UPSI or when 
using a traditional method such as withdrawal. The mechanism is claimed to be hindering the 
conceptus to implant in the uterus. This particular compound has shown some anti-ovulatory 
properties in rabbit [28], variable and contradicting effects on inhibition of implantation in 
rat, and effective inhibition of implantation when administered postcoitally in mouse [29]. 
The mechanisms suggested for the postfertilizing effects are interference with progesterone 
synthesis by terpenoids in the seeds [30]. 
2.5 EMERGENCY CONTRACEPTION IN MODERN TIMES  
2.5.1 High-dose Estrogens 
After the discovery that estrogens could prevent pregnancy in mammals in the 1920s, 
veterinarians started to administer estrogen to horses and dogs that had mated out of owner 
control [31, 32]. In the late 1960s, postcoital treatment with high-dose estrogens like 
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diethylstilbestrol (DES) or EE within 72 h after UPSI was proved effective and introduced 
also for women in order to prevent pregnancy. Due to risk of vaginal cancer and anomalies in 
the reproductive tract of the offspring with DES treatment, the most common regimen 
subsequently consisted of 5 mg EE daily for 5 days. Endometrial biopsies revealed a retarded 
pattern after treatment. There were further considerable side effects with the treatment of 
mainly nausea and vomiting. The androgenic progestogen Danazol in a two-dose regimen 
starting within 72 h from an UPSI has also been used for EC, however due to higher efficacy 
with other compounds developed, this treatment was rather short-lived [33]. 
2.5.2 The Yuzpe regimen 
The successful Yuzpe method was first described by Canadian physician Dr Albert Yuzpe in 
the 1970s and became a widely spread regimen that outrivaled and replaced previous high-
dose estrogen methods. The initial hormonal combination consisted of a single dose of the 
progestin dl-norgestrel and EE [34]. Further development resulted in the regimen 200 µg EE 
and 1 mg LNG, divided into 2 doses with 12 h apart, the first taken within 72 h from UPSI. 
Several studies have concluded its efficacy, although side effects such as nausea, vomiting 
and breast tenderness were commonly reported [35, 36]. An advantage of this method was 
that the active ingredients were the same as in many types of regular COCP, which made it 
quite easy for women to get hold of the correct treatment and subsequently take an adequate 
number of tablets. The side effects were similar to that of high-dose estrogen, however they 
occurred to a lesser degree. The main mechanism of action of the Yuzpe regimen has been 
shown to be through an effect on follicular development and ovulation and not on 
endometrial function [37]. The Yuzpe regimen was the standard ECP method up until the 
1990s. Only one previous study investigated the effect of a COCP containing another 
progestin than LNG for use as EC, namely norethindrone, and seemingly that regimen is safe 
and effective as EC as well [38]. 
2.6 CURRENT EC METHODS 
Mono-treatment with mifepristone or LNG, thus without estrogen, was introduced in the 
1990s and demonstrated higher efficacy and lesser side effects than the Yuzpe treatment and 
thus replaced this regimen. It consequently became the gold standard [35, 39]. The Yuzpe 
regimen is however still being used in countries lacking more effective EC options, 
considered as a dedicated ECP, and remains on the WHO EML. If no dedicated EC method is 
available, it is possible for a woman to use a specified number of regular COCPs containing 
EE and LNG as EC (as Yuzpe). The treatment includes intake of tablets in 2 doses with 12 h 
apart and the number of tablets needed depends on the hormonal content of that particular 
combination, ranging between 4-6 tablets for the most common preparations [40]. LNG 
containing regular Progestin-only Pills (POP) can also be used as EC and similarly the 
number of tablets needed vary depending on hormonal content. 
Current dedicated EC methods include insertion of a Cu-IUD or intake of a hormonal ECP in 
a single oral dose, either LNG or one of the PRMs mifepristone or UPA, although 
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mifepristone is available for this purpose only in a very limited number of countries. With 
almost no medical contraindications, the current dedicated ECPs are safe and in addition 
perceived tolerable by women. 
2.6.1 Copper Intrauterine Device 
The most effective EC option is undoubtedly insertion of a copper intrauterine device (Cu-
IUD) within 5 days after ovulation, which has an extremely low failure rate of 0.09% [19]. 
Since ovulation is difficult to assess, current recommendation is insertion within 5 days after 
UPSI. Turok et al however demonstrated that placement of a Cu-IUD for EC at any time in 
the menstrual cycle is highly effective, provided a negative urine pregnancy test prior to 
insertion [41]. The propensity to function as a long-term contraceptive for several years after 
placement is an additional advantage for this EC method.  
The main mechanism of action when a Cu-IUD is used for regular contraception is the toxic 
effect on spermatozoa, interference with fertilization and early embryo development and in 
addition to render the endometrium unreceptive for an implanting embryo in the unlikely 
event that it would reach the uterus [42, 43]. When used continuously, it does not interfere 
with the normal cycling characteristic development of the endometrium [44], however it can 
alter certain receptivity markers [45].  
The contraceptive mechanism when used for EC depends on when in the menstrual cycle the 
Cu-IUD is inserted. If pre-ovulatory, it may prevent fertilization in a similar way as when 
used for routine contraception, while postovulatory insertion but before implantation most 
probably inhibits implantation. These postfertilizing effects are not that of an abortifacient, 
but consist of preventing implantation at the endometrial level, which makes insertion of a 
Cu-IUD a superior method of EC [46]. Unfortunately, health care providers frequently fail to 
inform about this EC option and women are generally unaware of the effectiveness of the 
method. Furthermore, many women prefer hormonal ECPs as oral intake often is conceived 
as more convenient and in addition does not require access to insertion by a health care 
professional. There are currently ongoing clinical trials on the use of the LNG-releasing 
intrauterine system (LNG-IUS) for EC, with and without administration of LNG-EC orally 
prior to insertion. Such studies are welcome since hormonal IUD is increasingly preferred as 
a method for ongoing contraception due to its beneficial profile regarding improvement of 
menstrual related symptoms. 
2.6.2 Levonorgestrel 
Levonorgestrel-EC (LNG) is the most widely available ECP worldwide. Several studies have 
demonstrated LNG to be significantly more effective than the Yuzpe regimen and further 
with less side effects compared to the Yuzpe regimen [35, 47, 48]. Initially, LNG-only ECPs 
were administered in a two-dose regimen with intake of 0.75 mg within 72 hours from UPSI 
and a repeated dose of 0.75 mg 12 hours later. Several studies thereafter could demonstrate 
that a single LNG dose of 1.5 mg was equally effective so the recommended regimen 
switched, proving beneficial in terms of compliance [49, 50].  
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The mechanism of action of LNG when used for EC is delaying or inhibiting the Luteinizing 
hormone (LH) surge, which in turn delays or inhibits ovulation [51, 52]. Should LNG be 
administered after onset of the LH surge however, it has no ability to interfere with the 
ovulatory process and thus has no preventive contraceptive effect [52, 53]. Interestingly 
however, is that addition of the non-steroid anti-inflammatory drug (NSAID) meloxicam to 
LNG significantly prevented more follicles from rupturing than with LNG alone at an 
advanced stage [53, 54]. 
An effect of LNG on cervical and uterine mucus, which normally contributes to the 
contraceptive effect when used as regular contraception, is not likely contributing to the EC 
effect when postcoitally administered, and viable spermatozoa have been observed in the 
genital tract 24-48 h after LNG intake [55]. LNG-EC administered pre- or post-ovulatory 
does not significantly alter endometrial morphology or receptivity markers [51, 56]. Neither 
does it have an adverse effect on embryo viability or inhibit the process of human embryo 
implantation, as demonstrated in vitro [57]. A prospective cohort study of pregnancies after 
LNG-EC failure found no negative association between pregnancy outcome and LNG 
exposure [58]. The effectiveness of LNG decreases as the time between UPSI and treatment 
increases when used for up to 120 h after UPSI, with significantly higher failure rates after 72 
h [59]. Thus it is recommended for use within 72 h. However, where no other dedicated 
option is available it is being used for up to 120 h after UPSI.  
2.6.3 Progesterone Receptor Modulators mifepristone and UPA  
2.6.3.1 Mifepristone  
The first generation PRM mifepristone, moreover the most well known, is a synthetic steroid 
hormone with approximately two times greater affinity for the PR than progesterone in 
humans [60]. Mifepristone administered in a single high dose of 200 mg in combination with 
a prostaglandin analogue is a well-established regimen for medical induced abortion [61].  
The effect of mifepristone depends on the dose and stage of menstrual cycle when 
administered due to the concentrations of mifepristone and progesterone, respectively, as well 
as the expression of PRs in the target tissue at that specific time [62]. A single high pre-
ovulatory mifepristone dose of 200-600 mg will inhibit follicular development and ovulation, 
and ovulation will not resume until a new dominant follicle has been recruited [63, 64]. On 
average it takes approximately 3 weeks for ovulation to be resumed after early medically 
induced abortion, however for some women ovulation resumes as early as 8 days following 
intake of 200 mg mifepristone [65].  
Initially high doses of mifepristone were tested and proved effective for EC [36], however 
lower doses demonstrated equal efficacy with the advantage of less delay in subsequent 
menstruation compared to a higher dose [66]. Low pre-ovulatory doses of 10-25 mg disrupt 
follicular development and delay or block ovulation in a dose-dependent manner, which 
makes such a regimen effective and suitable for EC [51, 59, 67]. However, presumably due to 
the association with abortion and thus for political reasons, mifepristone for EC is currently 
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available in a limited numbers of countries, namely China, Moldova, Russia, Ukraine and 
Vietnam [40]. 
2.6.3.2 Ulipristal Acetate 
The so-called second generation PRM UPA is the most recent contribution to hormonal EC, 
for which it was specifically developed. It is administered as a single dose of 30 mg within 
120 h after UPSI and was approved by the European Medicines Agency (EMA) 2009 and 
further authorized to be accessible from pharmacies without prescription from a doctor in all 
European states 2015. 
Clinical trials comparing the failure rate of different ECPs have concluded that UPA is 
superior to the worldwide gold standard LNG in preventing unwanted pregnancies and 
should be recommended as first choice where available [18, 68, 69]. A meta-analysis with 
combined data from past clinical randomized controlled trials showed a significant reduction 
in pregnancy rates after UPSI for women who were treated with UPA compared to those who 
received LNG. If UPA was administered within 72 hours after UPSI the risk was halved and 
when administered within 24 hours, UPA lowered the risk by almost two thirds compared 
with LNG [18, 70].  
In a series of pharmacodynamic studies comparing different oral EC regimens, Brache et al 
demonstrated that UPA was more effective than LNG in preventing follicular rupture at a late 
follicular stage when the risk of conception is high [52, 53, 71]. UPA administered before the 
onset of the LH surge inhibited 100% of follicular ruptures. When administered after the 
onset of the LH surge, but before the LH peak, UPA inhibited 79% of follicular ruptures, and 
even at a very late pre-ovulatory state with a mean follicle diameter of 18 mm, ovulation was 
delayed by UPA for at least 5 days in 59% of women [71]. The higher efficacy is thus 
seemingly due to a wider time window of effect, where UPA can inhibit follicular rupture and 
delay ovulation beyond the life span of sperm. This effect is maintained even when 
administered at an advanced phase of follicular development, after the onset of the LH surge, 
where LNG is no more effective than placebo. However, when the risk of conception is at its 
highest around the time of ovulation, at or after the LH peak, none of currently available 
ECPs can prevent follicle rupture. 
2.7 ENDOMETRIAL EFFECTS OF MIFEPRISTONE AND UPA 
2.7.1 Mifepristone 
High doses of mifepristone affect implantation due to inhibition of endometrial development 
[62, 72, 73] and administration of a single high dose of mifepristone 200 mg once monthly on 
menstrual cycle day LH+2 (LH peak = 0) has been demonstrated to be an effective method of 
contraception without altering the menstrual cycle and for most part maintaining monthly 
ovulations [72, 74]. The regimen of a once-a-month pill is unfortunately not very feasible in 
clinical practice as timing of treatment is essential. 
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 The effect of a high concentration of mifepristone (10 µM) on human embryo implantation 
process has further been studied more closely in vitro, in a 3D endometrial co-culture system. 
None of the embryos in the mifepristone group attached to the construct, whereas embryos in 
the LNG treated cultures could attach to the cultures [57]. Mifepristone in a single post-
ovulatory dose of 10 mg rendered the endometrium slightly out of phase and to a limited 
extent affected studied endometrial receptivity markers [51]. This dose was consequently not 
sufficient to prevent pregnancy when given once weekly and almost half of the women had 
monthly ovulations with this regimen [75]. In contrast, clinical trials with mifepristone given 
weekly in doses of 25 or 50 mg have been successful in preventing pregnancy [76] although 
inconsistent in inhibiting ovulation [77]. The preventive effect is presumably due mainly to 
endometrial impact. Very low doses that do not impair ovulation cause asynchronous 
endometrial changes when administered orally daily or weekly, however are not very 
effective to inhibit endometrial receptivity and implantation as evidenced by high pregnancy 
rates in clinical studies [75, 78, 79]. The threshold for continuous inhibition of ovulation has 
been estimated at a daily dose of 2 to 5 mg, which in a majority of women also causes 
amenorrhea [80-85]. Whether or not the pronounced endometrial changes caused by these 
regimens would permit embryo implantation had not been studied for the human embryo 
implantation process.  
2.7.2 Ulipristal Acetate 
Since UPA is a similar compound to mifepristone and more effective than LNG in preventing 
pregnancies without decrease in effect if taken within the 5 days following an UPSI, 
questions have been raised as to whether the mechanism of action of UPA involves 
postfertilizing effects on the endometrium and embryo implantation [86]. UPA has, similar to 
mifepristone, a dose-dependent effect on the endometrium and high or repeated doses affect 
endometrial histology with reduced endometrial thickness and inhibition of down-regulation 
of PRs. In low doses, such as those relevant for EC, UPA does not significantly delay 
maturation compared to placebo, although minor endometrial changes have been observed 
[87, 88]. 
UPA affects human spermatozoa to some degree, such as progesterone-induced acrosome 
reaction, intracellular calcium concentration and hyperactivation. However, the effect is not 
believed to be of any significance for EC since several other qualities of importance (such as 
viability, motility and capacitation) are not affected [89]. Consequently, a recent study could 
demonstrate that UPA in a concentration corresponding to EC dose did not have any effect on 
fertilizing abilities of human sperm [90]. Li et al have showed that UPA could effect tubal 
function to some extent [91], however speculated that this should not possess a post-
ovulatory effect on sperm since they can be retrieved in the fallopian tubes 5-10 mins after 
UPSI [92, 93]. 
There are still few reported pregnancies after intake of UPA for EC and the manufacturer of 
UPA-EC has established a pregnancy registry in order to collect info on treatment failure 
(pregnancies occuring despite EC use) or pregnancies unrecognized at intake. A report from 
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postmarketing surveillance of UPA showed no evidence of teratogenic effects after treatment 
with EC. However, the number of exposed pregnancies was small, suggested due to 
unwanted pregnancies being terminated or non-reported if uncomplicated [94]. The direct 
effect of UPA on human embryo implantation had not been studied when this project started. 
2.8 THE FERTILE WINDOW AND PREGNANCY RISK 
An UPSI can result in pregnancy during a limited time in the menstrual cycle, ranging from 
approximately 5 days before to 1 day after ovulation, due to the survival length of 
spermatozoa in the female reproductive tract (120 h) as well as the life span of the oocyte 
after ovulation (12-24 h). The fertile window varies in accordance with the time of ovulation 
and the highest rates of conception have been observed within two days prior to ovulation 
[95, 96]. 
2.8.1 Probability of conception 
The number of expected pregnancies was initially estimated based on conception 
probabilities by cycle day of UPSI relative to the day of ovulation, however since it is 
difficult to assess ovulation and assessments become imprecise it is most often estimated 
based on conception probabilities by cycle day of UPSI relative to the first day of bleeding. 
These estimates show that there are only two days of the menstrual cycle in which a woman 
faces zero risk of pregnancy and that is the two first days of her cycle [97]. 
 
          
         Figure 3. Probability of being in the fertile window for women with regular 
            or irregular cycles. Modified from Wilcox, Dunson and Baird, BMJ 2000 
 
2.9 EC EFFECTIVENESS 
Clinical studies of EC efficacy are for ethical reasons most often designed as comparison 
trials between different EC methods instead of randomized placebo controlled trials. It is 
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therefore difficult to assess the actual effectiveness for each method to reduce the risk of 
pregnancy. The estimated efficacy is instead calculated based upon assumptions of the 
theoretical baseline risk for the particular woman depending on when in the menstrual cycle 
the act of UPSI took place, and how long before EC intake. These rates are further compared 
with the actual number of pregnancies after EC administration in clinical EC trials [40].  
Currently available EC options have been estimated to prevent 57-99% of pregnancies, 
depending on method and when used in the menstrual cycle [18, 19, 35, 49, 98]. As Trussell 
et al correctly point out; accuracy in estimating EC efficacy depends on how accurate data is 
of menstrual cycle day and timing of UPSI [40]. Among women seeking EC in one study, 
over 30% inaccurately dated their cycles as being in the fertile period when they were not 
[99]. An even greater proportion with nearly half of women reporting a menstrual cycle day 
incompatible with hormonal measures had in addition been seen previously [100]. These 
observations have rendered arguments that EC effectiveness in fact might be overstated. On 
the other hand, 60% of women in the above study had engaged in more than one act of sexual 
intercourse when requesting EC and although for the most part reporting use of a barrier 
method at that occasion [99], a possible pregnancy due to a previous intercourse risks to 
doom EC treatment as having failed. Further, Li et al concluded that EC might be more 
effective than estimated when they reanalyzed data from previous studies on the probability 
of conception after the act of UPSI and in addition considered that it does not occur 
independently of ovulation [22].  
Ultimately, calculating EC efficacy by comparing failure rates with different methods in 
clinical trials might be the most accurate approach. As argued in a recent review article with 
the example taken of combined data from comparison trials with the Yuzpe regimen and 
LNG [47, 48, 101]; as the number of pregnancies in women who received LNG was 
approximately half of those who received Yuzpe (RR 0.51), the LNG regimen should at least 
have an efficacy of 49% if Yuzpe was completely inefficacious. Additional efficacy points of 
the Yuzpe regimen would thus add further points of efficacy to the LNG regimen [40]. 
2.9.1 Risk factors for EC failure 
2.9.1.1 Cycle day of Unprotected Sexual Intercourse 
Risk factors associated with EC failure have been identified after compilation of data from 
conducted clinical studies and as expected, the cycle day of UPSI was significantly associated 
with pregnancy with the highest risk at the time of ovulation, independent of ECP type [102]. 
2.9.1.2 Treatment delay 
With increasing treatment delay after UPSI, the risk of nearing an ovulation is greater and 
thus supposedly EC failure. Regarding effectiveness of treatment, several studies have shown 
that LNG is more effective if taken closer to the UPSI, with decreasing effect as the interval 
between UPSI and EC increases, markedly after 72 h [17]. Similarly, even when adjusted for 
cycle day when UPSI took place, treatment delay has demonstrated to decrease efficacy 
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[103]. In contrast, a combined analysis from pooled data of four WHO trials concluded that 
not until on day 5, after 96 h, was a decline in efficacy observed with LNG [104]. There is no 
decline in efficacy for the PRMs mifepristone and UPA [18, 59, 105].   
2.9.1.3 Further Acts of Unprotected Sexual Intercourse 
Since follicular development and ovulation usually resume within a week after intake of an 
ECP, women are at risk of becoming pregnant if further acts of UPSI take place in the same 
cycle due to timing of a postponed follicular rupture and ovulation, regardless of which ECP 
method is used. Glasier et al demonstrated that women who had further acts of UPSI after 
ECP use were four times more likely to get pregnant than were those who did not report such 
an event, with no difference in between the groups treated with UPA or LNG [102]. This 
finding is consistent with the meta-analysis in a Cochrane review which concluded that the 
pregnancy risk was approximately 3 times higher for women who had further acts of UPSI in 
the same cycle as ECP treatment, than for women who did not [17].  
2.9.1.4 Body Mass Index  
The variable Body Mass Index (BMI) had a significant impact on pregnancy risk with a 3 
times greater risk for a woman with BMI above 30, compared with women who had BMI 
below 25. This increased risk was more pronounced for women treated with LNG compared 
to UPA, where LNG was no more effective than no treatment in women with BMI above 26, 
while loss of effectiveness with UPA was calculated to BMI 35. These trials were however 
not initially designed to study these relationships and the number of overweight and obese 
women was limited, as were the number of pregnancies [102]. The debate over what 
influence BMI and weight prepossess on the effect of EC has been vivid as it in some 
instances caused that women were denied treatment due to their weight.  
Pooled analysis from four large clinical WHO trials showed an increased pregnancy rate in 
obese women. However, when excluding one site in the analysis, the impact of obesity did no 
longer have an apparent impact on LNG efficacy, with the reservation that few obese women 
in the latter analysis were included [106]. Current recommendations are that women of all 
weights should be provided ECP when needed since the benefits outweigh the risks of 
decrease in effectiveness. However, it has been shown that obesity has a negative impact of 
LNG-EC pharmacokinetics and that doubling the dose adjusts for reduced concentration in 
serum to levels seen in women with normal weight [107]. If this approach is correct and 
should lead to updated guidelines for effective treatment with LNG-EC in an overweight 
population remains to be elucidated.  
2.10 QUICKSTART OF REGULAR CONTRACEPTION 
Except for being the most effective EC method, with no reduction in effectiveness over time, 
including should further acts of UPSI take place or have occurred at the time of ovulation, or 
in regards to BMI, insertion of a Cu-IUD also has the additional propensity of serving as an 
effective ongoing and long-term contraception if left in place [108, 109]. In the view of 
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reducing pregnancy risk after ECP treatment, it is of great importance to take the opportunity 
to initiate a more effective regular contraceptive method when a woman seeks EC, as she 
most likely is motivated to do so at this time. In this capacity, EC could serve as a gateway to 
bridging over to long-term regular contraception. In a recent pharmacy-based intervention 
study in the UK, a higher proportion of women who were provided with a packet of 
progestogen only pill (POP) for temporary contraception when purchasing LNG-EC, were 
using a regular method after two months compared to those who only received the ECP 
[110]. 
There is an ongoing discussion regarding “quick-starting” contraception after ECP treatment, 
a term which refers to initiating a regular contraceptive method immediately after ECP use. 
The perspective is that the sooner a woman starts with a regular method, the sooner she will 
be protected from an unwanted pregnancy. It is recommended for women to use a barrier 
method for contraception or abstain from sexual intercourse for the first 7 days of treatment 
with a regular oral contraceptive pill following LNG-EC intake, which is the time expected 
until the regular contraception can be completely relied on for contraception, as otherwise 
when starting such treatment mid-cycle [16]. 
Regarding UPA, there are concerns that quick-starting contraception after EC intake could 
potentially jeopardize contraception for a longer time initially, due to possible interference of 
UPA with progestin-containing contraceptives at the PR site. This could alter the 
effectiveness of hormonal contraception and vice versa. When this project started, current 
advice to women who quickstarted an oral hormonal contraceptive pill after UPA treatment, 
was to abstain from sexual intercourse or to use a barrier method until the next menses before 
the regular contraception could be fully relied upon for contraception [111].  
The information on the possible interaction between UPA and a regular oral hormonal 
contraceptive pill is necessary so that women can be provided with evidence-based advice on 
the most effective ways to reduce risk of pregnancy following EC use. 
2.10.1 Barriers to use of regular contraception and EC 
Efforts made have increased availability of EC worldwide and the method is well recognized 
nowadays, however access is still limited and unequally spread, as well as lacking in many 
settings (http://www.cecinfo.org) (accessed April 2017). Limited access in countries where 
EC is registered is due to various factors, such as cost, whether accessible only by 
prescription, behind-the-counter or OTC, as well as the woman’s age or marital status, where 
consequently young women are denied access. Unintended pregnancies could be avoided if 
barriers to the use of effective contraceptive methods would be reduced, however knowledge 
of EC as a possible method to prevent pregnancy is also unequally spread around the world 
[112].  
Many factors contribute to the limited access and availability of EC for women globally. 
There are political and legislative, as well as religious and moral actions in many countries 
around the world in opposition against EC. Some of the myths and misconceptions 
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surrounding EC concern mechanisms of action of these methods where EC is often confused 
with induced abortion. There are further concerns that postcoital contraception possesses 
postfertilizing effects on the endometrial function and embryo implantation, should ovulation 
and fertilization have taken place before EC action. In the name of the catholic doctrine, the 
state of Vatican City opposes the use of EC and in a statement inaccurately declares that use 
of EC is a chemically induced abortion and furthermore that women seeking EC as well as 
EC providers wish to terminate a pregnancy in progress 
(http://www.vatican.va/roman_curia/pontifical_academies/acdlife/documents/rc_pa_acdlife_
doc_20001031_pillola-giorno-dopo_en.html) (accessed April 2017). 
Lack of knowledge of mechanisms of action for EC is not only limited to women and the 
general public, but also exists among health care providers treating them. Although several 
reports have concluded that EC availability does not increase the rates of UPSI or sexually 
transmitted infections, nor adversely affect the use of regular contraception [113-116], these 
concerns are still regularly expressed. 
Sedgh and Hussain examined reported reasons for not using regular contraception among 
married women with an unmet need in developing countries between 2006 and 2013. The 
reasons were diverse and included not having access to contraceptive services, opposition to 
contraception due to the woman’s or partners religious or personal beliefs and breastfeeding 
among others. The most common reasons were however fear of side effects and health risks 
and infrequent sex. Nonetheless, at least half of the women who reported that the reason for 
not using contraception was due to infrequent sexual activity actually had had sex within the 
three recent months. The authors concluded that women with an unmet need of contraception 
would benefit from having access to contraceptive services where they could seek counseling 
and information, which includes help to select an appropriate method among a range of 
methods possible to choose from [117].  
 
2.11 THE FEMALE REPRODUCTIVE SYSTEM 
The female reproductive organs are located in the pelvis and include the uterus with cervix, 
vagina, ovaries and fallopian tubes. The pear-shaped uterus consists of three anatomical 
layers; the thin outer layer serosa, the thick middle smooth muscle layer myometrium and the 
inner mucosal layer endometrium (Figure 4). The uterus is highly responsive to ovarian 
hormones where the endometrium in a cyclic manner monthly prepares to receive a fertilized 
egg and if so with ability to maintain a pregnancy, or in absence of implantation, shed with 
subsequent self-renewal. 
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Figure 4. The female reproductive system  
Source: National Cancer Institute, via Wikimedia Commons  
 
2.11.1 The Endometrium and endometrial cells 
The endometrium consists of two layers; the basal layer adjacent to the myometrium, and the 
upper functional layer outwards the uterine lumen with the surface epithelium on top. The 
functional layer is highly sensitive and responsive to ovarian hormonal fluctuations and 
displays cyclic proliferative, secretory and degenerative changes, where it ultimately sheds 
during menstruation. The basal layer however is retained after menstruation and is the source 
for endometrial regeneration in future cycles (Figure 5). The endometrium is composed of 
several cell types, the two major being endometrial epithelial cells (both luminal and 
glandular) and endometrial stromal cells. In addition, the endometrium contains endothelial 
cells, stem cells and fluctuating levels of immune cells [118]. 
2.11.1.1 Epithelial and Stromal cells 
The endometrial epithelial cells make up a single layer of columnar cells, lining the luminal 
surface and the glands. The luminal epithelial cells are normally covered with repellent 
protective glycocalyx molecules, not allowing opposing uterine or embryonic cells to adhere. 
At the window of implantation (WOI) however, the epithelial cells acquire a state of 
receptivity where loss of inhibitory components and upregulation of cell-adhesion molecules 
permits an embryo to attach. The glandular epithelial cells secrete autocrine and paracrine 
factors of importance for endometrial maturation as well as for embryo implantation.  
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The stromal cells are located in the connective tissue-like stromal compartment, which 
predominantly consists of proteoglycans and collagen. These fibroblast-like cells produce 
extracellular matrix (ECM) including a range of proteins such as matrix metalloproteinases 
(MMPs) and tissue inhibitor of metalloproteinases (TIMPs) as well as growth factors and 
cytokines. In further preparation for implantation, edema increases throughout the stromal 
compartment and the stromal cells become less densely packed [119]. Stromal cells are 
furthermore located adjacent of endometrial spiral arteries where they are important for 
angiogenesis during the menstrual cycle and pregnancy. At the time of ovulation, mitosis of 
the stromal cells reaches a maximum and they are further increased nearing the menstrual 
phase, however in the peri-implantation period mitosis decreases markedly [120].  
2.11.1.2 Leukocytes 
In addition to epithelial and stromal cells, the endometrium contains a substantial leukocyte 
population that varies during the normal menstrual cycle, as well as during pregnancy. The 
regulating mechanisms for this dynamic process are not fully understood but are believed to 
involve interactions between steroid hormones and factors that are produced by the 
endometrial cells, as well as from trophoblast cells during pregnancy. The endometrial 
leukocytes are mainly located within the stroma and the main leukocyte cell types are uterine 
natural killer (uNK) cells, macrophages and T lymphocytes [121]. Uterine NK (uNK) cells 
are the major leukocyte population in non-pregnant secretory endometrium as well as in 
decidua during early pregnancy. uNK cells proliferate and differentiate in the uterus but their 
origin is debated. They probably originate from early NK progenitors recruited from blood. 
However several pathways are possible [122].  
In the normal cycling endometrium, uNK cells proliferate and accumulate in the stroma 
postovulatory, with a dramatic increase from the mid-secretory phase as response to [121] 
circulating progesterone and through early pregnancy if such occurs. The influence from 
progesterone is indirect since uNK cells themselves lack the PR [121]. In studies exploring 
these mechanisms through treatment with antiprogestins, the IL-15 pathway has been 
identified as a key network in uNK development and function, where IL-15 mediates the 
differentiation of immature to mature uNK cells. IL-15 expression in endometrium correlates 
with circulating progesterone levels as well as with uNK cells and decreases in response to 
treatment with antiprogestins. Treatment with the antiprogestin Asoprisnil dramatically 
reduces the number of uNK cells in the endometrium and histological examination of tissue 
after exposure demonstrates altered vascular architecture [123]. 
2.11.1.3 Stem cells 
The basal layer of the endometrium contains stem cells with the intrinsic capacity of 
regenerating the functional layer and surface epithelium every month during the reproductive 
years [124]. This knowledge has opened up for the exciting research field of endometrial 
stem cells, which have been shown to also shed during menstruation. Thus, menstrual blood 
provides a source of stem cells that can be collected non-invasively. Hopefully in the future 
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this may lead to novel treatment possibilities for women suffering from Ascherman’s 
syndrome or infertility disorder due to endometriosis. 
2.11.1.4 Endothelial cells 
Endothelial cells in the endometrial vasculature are regulated by changes in levels of estrogen 
and progesterone during the menstrual cycle. Angiogenesis has a central role in the menstrual 
cycle during the dynamic events of endometrial regeneration and maturation. It is initiated to 
repair the endometrial vasculature during menstruation and new vessels are further generated 
from pre-existing ones during the proliferative phase. Angiogenesis moreover continues 
during the secretory phase when spiral arteries grow and coil and in the development of the 
subepithelial capillary plexus [125]. Thus, the endometrium becomes richly vascularized in 
time for implantation.  
The endothelial cells express ERβ and are stimulated to grow in responsive to estrogen [126]. 
However, they seemingly do not express PRs, although demonstrated to respond to 
progesterone withdrawal, which is believed to be due to paracrine factors mediated by 
stromal cells close to the vessels [127]. Helmestam et al demonstrated that mifepristone 
significantly reduced tube formation in endothelial cells when epithelial cells and stromal 
cells were co-cultured compared to mono-cultured epithelial cells, why the authors concluded 
that the stromal cells probably influenced the effect of mifepristone through paracrine 
mechanisms [128]. 
                           
Figure 5. Endometrial morphology with Basalis and Functionalis layers 
 
2.11.2 Hormonal regulation of the endometrial cycle 
Each menstrual cycle begins with the first day of menstruation, cycle day one. Ovulation 
occurs 14 days before onset of the subsequent menstruation, approximately on cycle day 14 
in an average menstrual cycle of 28 days. During a woman’s reproductive life in the 
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developed world, these continuous cyclic events of regeneration and shedding take place 
more than 400 times [118]. 
2.11.2.1 Ovarian cycle 
Pulsatile secretion of GnRH from the hypothalamus regulates production of gonadotropin 
hormones, which are secreted from the pituitary gland in a similar pulsatile manner. The 
gonadotropin hormones follicle stimulating hormone (FSH) and LH control the ovarian 
function by inducing sex steroid secretion and follicular growth. [129]. FSH stimulates the 
development of ovarian follicles by acting on granulosa cells in preantral and antral follicles 
leading to conversion from androgens to estrogens with help from aromatase enzyme. The 
granulosa cells surrounding the oocyte proliferate under FSH influence and FSH and estrogen 
further stimulate the production of follicular fluid.  
The theca cells in the larger follicles express LH receptors and in response to LH produce 
androgens, which are transported to the neighbouring granulosa cells and subsequently 
converted into estrogens as described. The pulsatile frequency and amplitude of gonadotropin 
hormones determine the amount of steroid hormones to be produced and further varies due to 
feedback mechanism from hormones produced [129]. In addition, the preovulatory follicle 
synthesizes progesterone, which slows down follicular growth and suppresses apoptosis and 
mitosis through the progesterone receptor membrane component-1 (PGRMC1) in the 
granulosa cells.  
The LH surge initiates angiogenesis of the ovulatory follicle through angiogenic factors in 
granulosa cells, including production of the key regulator prostaglandin E2 (PGE2) [130, 
131]. PR signaling further induces expression of gene products necessary for follicular 
rupture [132]. Ovulation occurs approximately 36 hours after the LH peak and around 14 
days before the subsequent menstruation. The former dominant follicle thereafter transforms 
into the corpus luteum with cells luteinized by LH. Angiogenic factors increase the blood 
supply, which permits the precursor cholesterol to reach the cells of the corpus luteum and be 
converted to progesterone. Postovulatory progesterone levels increase to above 10 ng/ml, 
with a peak during the mid-lutel phase (Filicori 1984). If conception and implantation does 
not take place, regression of the corpus luteum occurs rapidly 9-11 days postovulation.  
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Figure 6. The menstrual cycle. Modified from  
Wikimedia Commons and Encyclopedia Britannica 2008. 
 
2.11.2.2 Endometrial cycle 
During the endometrial cycle, the functional layer of the endometrium undergoes 
morphological and functional changes in a cyclic manner in response to ovarian steroid 
hormones. The endometrial cycle is divided into three phases, each with typical histological 
features; the menstrual phase, the proliferative phase and the secretory phase, the latter can in 
turn further be divided into early secretory and mid to late secretory phases. The menstrual 
and the proliferative phases occur during the ovarian follicular phase and the secretory phase 
during the ovarian luteal phase (Figure 6) [118]. Although continuously in change, the 
endometrial alterations follow a specific, regular, sequenced pattern, which makes it possible 
to date the endometrium histologically from endometrial biopsies.  The classical 
morphological criteria for evaluating endometrial development, established by Noyes’ et al in 
the 1950s is still used and referred to [119]. However it has also been questioned whether it is 
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suitable for clinical guidance regarding evaluation of a receptive endometrium [133] or if it is 
a reliable tool for menstrual cycle day assessment [134].   
Estrogen and progesterone receptor expression in the endometrial cells change dynamically 
during the menstrual cycle. Estrogen receptors are predominantly expressed in stromal cells 
during the proliferative phase, however the concentration falls drastically under the influence 
of progesterone in the luteal phase. Progesterone facilitates the action of estradiol in inducing 
the LH surge that triggers ovulation [135]. Progesterone is essential in initiation and 
maintenance of pregnancy and stimulates the proliferation and differentiation of stromal cells. 
PR expression in endometrial glandular epithelium peaks in the late follicular and early luteal 
phase with a decline at the mid-secretory phase, whereas in stromal cells PR expression 
shows only minor fluctuations [136, 137]. 
Estrogen secreted during the follicular phase exerts mitogenic effects on the endometrial 
tissue, inducing growth as well as angiogenesis of spiral arteries of the endometrium. 
Estrogen increases PR expression, which permits the endometrium to respond to progesterone 
that is produced during the following postovulatory luteal phase. The endometrium is 
regulated by both estrogen and progesterone during the early secretory phase, however 
characterized by progesterone dominance during the mid-secretory phase and progesterone 
withdrawal in the late secretory phase. Progesterone shifts the endometrium into a highly 
secretory state by inducing differentiation in the endometrial glandular epithelium as well as 
in the stromal compartment. The epithelial glands become increasingly tortuous with increase 
in secretory activity and produce a number of cytokines and growth factors with the purpose 
to facilitate implantation should fertilization occur. The stromal cells likewise respond to 
progesterone and differentiate into decidual cells during the secretory phase. 
2.11.2.3 Decidualization 
The stromal cells are elongated fibroblast-like cells that in response to progesterone transform 
into larger rounded specialized secretory decidual cells during the secretory phase. The 
decidualization process starts with the stromal cells close to the spiral arteries via endocrine 
influence and thereafter spread throughout the endometrial tissue through paracrine and 
autocrine signals. Decidualization involves remodeling of the ECM and vasculature along 
with the infiltration and/or proliferation of specific immune cells. The decidualization process 
in humans is independent of signals from a blastocyst, thus occuring in response to 
progesterone during the luteal phase in every normal cycle whether or not pregnancy occurs. 
The decidualized endometrial tissue is dependent on continuous progesterone stimulation in 
order to maintain its integrity [138].  
In the absence of fertilization and implantation, the estrogen and progesterone levels rapidly 
decrease due to regression of the transient corpus luteum. The abrupt hormonal withdrawal 
induces spasm of spiral arteries, followed by ischemia, an increase of proteolytic enzymes 
and apoptosis and results in destruction of the functional layer, which ends with shedding and 
thus onset of menstruation. 
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2.11.3 Window of implantation 
It is only during a short period of time in the menstrual cycle, in the mid-secretory phase, that 
the uterus will accept and accommodate the blastocyst. The receptive phase, or WOI refers to 
the time during the endometrial cycle when the endometrium under the critical influence by 
progesterone has transformed and attained receptivity necessary for successful embryo 
implantation. The WOI occurs during menstrual cycle days 20-24 when the postovulatory 
progesterone levels peak in serum in a regular cycle (Fig 6) [139].  
The receptive endometrium is characterized by a glandular epithelium that is differentiated 
into a secretory state and produces a repertoire of molecules, such as a variety of cytokines, 
growth factors and modulatory proteins that enables implantation. Following a coordinated 
dialogue between the competent blastocyst and the receptive endometrium, the embryo 
attaches to the epithelial cells and invades the endometrial stroma. The orchestrated process 
of embryo implantation is highly dynamic and includes a cascade of molecular signaling. 
Under the influence of ovarian hormones and paracrine secretions, the different uterine cells 
and extracellular matrix (ECM) interact in a spatiotemporally complex network to 
accommodate the embryo. The synchronous development of the endometrium and the 
implanting blastocyst is essential for adequate reciprocal communication between them and 
consequently for successful implantation [140]. In many mammals, the demise of 
preimplantation embryos is commonly occurring, suggested to be part of a natural 
endometrial selection process ensuring correct implantation of high quality embryos only 
[141]. In humans, the estimated implantation rate in natural cycles is estimated to less than 
30% [142].  
2.12 EMBRYO IMPLANTATION 
The fallopian tube catches the released oocyte at ovulation and if there are spermatozoa 
present, fertilization can occur. The fertilized oocyte thereafter migrates through the fallopian 
tube with help from beating motion of cilia and smooth muscular contractions, while 
undergoing regulated mitotic cleavage, and enters the uterus in the morula stage on cycle day 
17-18 [143]. After having floated freely in the cavity, it hatches out from the zona pellucida 
as a blastocyst stage embryo and arrives at the luminal epithelium 5-6 days postovulation. 
The blastocyst consists of an inner cell mass (ICM), which eventually develops into the 
embryo, and the outer trophectoderm layer, which eventually develops into the embryonic 
placenta. The blastocyst begins to implant day 20-21 in dialogue with the receptive 
endometrium [140].  
Embryonic trophoblast cells adhere to the endometrial epithelium and thereafter penetrate 
between the epithelial cells and invade through the underlying basal lamina, where some of 
the trophoblast cells fuse to form syncytial trophoblast (Figure 7). These cytotrophoblast cells 
become invasive extravillous trophoblast (EVT) and invade the maternal decidua as well as 
the inner third of the myometrium [144]. EVTs possess the ability to invade the decidua by 
producing large amounts of MMPs that degrade the ECM [145].  In order to ensure provision 
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of placental blood supply they further penetrate and remodel maternal blood vessels, thereby 
establishing contact between the embryo and the maternal blood supply. 
The endometrium has traditionally been considered as a passive tissue in the process of 
embryo invasion during implantation. However, more recent studies have shown that 
decidualized cells are highly active and migrate towards the implanting embryo, 
encapsulating it as well as providing a favorable matrix for trophoblast expansion. These 
migratory and invasive capacities are further enhanced by close contact with trophoblast 
cells. It is the dialogue between the decidua and blastocyst that orchestrates the dynamic 
process by which the blastocyst becomes completely embedded in the endometrium [146].  
The embryo-endometrial crosstalk requires a range of molecules, secreted from both the 
endometrium and the implanting blastocyst itself. Such factors include modulating proteins, 
such as growth factors and cytokines with corresponding receptors, cell-adhesion molecules, 
proteolytic enzymes and inhibitors among others. Interaction between these molecules forms 
cascades of molecular signaling into the endometrium [140, 147]. 
Several factors can repress or increase trophoblast invasion; autocrine factors from the 
trophoblast cells themselves or paracrine factors secreted from cells in the endometrium 
[148]. Decidualized cells produce a variety of cytokines and growth factors that are either 
stimulatory or inhibitory of invasion by regulating processes such as protease activity or 
expression of integrins. Pro-invasive factors including IL-1β, IL-6 and IL-15 mainly function 
by increasing MMPs and thereby invasion and migration of trophoblasts. In order to regulate 
trophoblast invasion, the decidua can also control and limit the trophoblast invasion by 
producing protease inhibitors and/or control the direction of invasion through chemoattractant 
substances. IL-10 holds anti-inflammatory and immunosuppressive properties and inhibits 
invasion of trophoblast cells but the underlying signaling mechanisms are not fully 
understood. Several chemokines promote trophoblast migration and adhesion on fibronectin 
and collagen through their chemotactic activities, which contributes with increased invasion 
into the decidua [144]. 
Chemokines and their receptors are central in the process of embryo implantation as they are 
involved in the recruitment of different immune cells necessary to generate the fetal-maternal 
interface. Trophoblast cells actively recruit immune cells, such as uNK cells, uterine 
macrophages and dendritic cells, through chemokine production. Trophoblast cells can also 
modulate different leukocyte subsets towards an immune tolerant microenvironment, 
including induction of regulatory T cells, to sustain homeostasis and successful invasion and 
acceptance from maternal tissue [149]. 
The switch from pro-inflammatory to an anti-inflammatory microenvironment in the uterus in 
the post-implantation stage is essential for successful establishment of pregnancy. For this 
reason, a functional redundancy of different mechanisms (many yet to be elucidated) that 
trigger immunomodulation from trophoblast cells has evolved. One of the demonstrated 
mechanisms include epigenetic silencing with methylation of T cell-attracting inflammatory 
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chemokines genes in decidualized stromal cells, thereby modulating these cells capacity of 
recruiting T cells [149]. 
 
Figure 7. Early embryo implantation. The blastocyst hatches out of the Zona pellucida, attaches to the surface 
epithelium of the endometrium and penetrates between the epithelial cells to invade the endometrial stroma 
 
2.12.1 Molecular markers of endometrial receptivity 
The uterus needs to become shifted towards a functionally receptive state where possible to 
perceive the blastocysts signals in order for it to implant in the uterine wall. Downstream 
target genes from the activated PR regulate uterine differentiation and a range of molecules in 
the hormonally primed endometrium is needed for allowing the blastocyst to implant.  
Several molecules of importance for embryo implantation during the WOI have been 
identified and studied. These markers of endometrial receptivity belong to different 
functional groups such as cell adhesion molecules, cytokines, transcription factors and 
decidualization factors.  
With the aim to understand endometrial receptivity and presumably in addition to find a key 
marker, scientists have explored the molecular signature of the receptive endometrium 
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through several approaches. No single suitable biomarker defining endometrial receptivity 
has been established but many potential markers are suggested. The list of candidates is also 
growing due to the rapid expansion of endometrial studies, including global gene expression 
studies [150-154]. Such studies have provided a vast amount of data, however often with low 
reproducibility and with variable results [155]. At the same time, the transcriptomic signature 
of the receptive endometrium has been identified through microarray and the more recent 
development of epigenetics and proteomics has further expanded knowledge [156]. In 
addition, development of the diagnostic tool Endometrial Receptivity Array (ERA) has made 
it possible to assess endometrial receptivity in biological samples, knowledge that could be 
used in the context of assisted reproductive technology (ART) when the reason for infertility 
is due to endometrial dysfunction [157]. 
2.12.2 Models to study embryo implantation 
In vivo studies of human embryo implantation are difficult to perform for technical and 
ethical reasons and proper models for studying this complex molecular process are lacking. 
Most of the information on the human embryo implantation process has derived from 
different animal or in vitro models. Advantages of using experimental animals include high 
fertility and predictable patterns of physiological responses that are easy to affect. Animal 
models have generated valuable information on certain phases of early embryo implantation. 
Investigations on genetically engineered mice have further yielded important knowledge 
about factors of importance for the implantation process [158, 159]. However, rodent or 
rabbit models have considerable limitations as the reproductive physiology such as 
endometrial function and type of implantation process is significantly different from humans.  
In contrast, the hormonal regulation and cyclic endometrial histological changes are similar to 
that of humans in a few non-human primates such as Rhesus monkeys (Macaca mulatta) and 
Cynomolgus monkeys (Macaca fascicularis). Studies of the embryo implantation process are 
however not very practical to conduct in larger scale in these species due to fairly low fertility 
in captivity and high cost.  On the other hand, non-human primate models have proven to be 
good for testing different contraceptive drugs. Altogether, both non-primate models and non-
human primate models have contributed with data on the mechanism of action of UPA and 
mifepristone on the endometrium and embryo implantation [160-164].  
Nevertheless, due to important differences between species and since the implantation 
process in humans undoubtedly is unique, several different in vitro cell culture systems using 
human endometrial cells and human trophoblast cells or embryos have evolved. Initially, in 
vitro studies of implantation were conducted using endometrial explants from rabbit [165]. 
Mid-secretory human endometrial explants have also been used and proven to successfully 
enable human embryo attachment [166]. Although this method perhaps simulated the state in 
vivo and in addition yielded important information, it conveyed challenges such as limited 
possible culturing length and difficulty to assess implantation due to toxic degeneration and 
necrosis of the tissue.  
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Advantages with two-dimensional in vitro cell culture models for implantation studies are 
that they generally are easier to carry out than more advanced, complex models [167]. 
However, they do not typically include several cell types and thereby do not consider the 
important network of interaction that occurs between endometrial cells in the in vivo tissue. 
The cells in these models are further grown in a monolayer on an artificial plastic surface 
with loss of important 3D features. Although having given valuable information on events 
during implantation [168, 169], 2D studies might be of limited predictive value of conditions 
in vivo.  
2.12.3 3D in vitro endometrial co-culture model 
In order to better imitate the architecture of physiological endometrium in vivo and to 
establish a uniform reliable and reproducible model for studies on the human embryo 
implantation process, an in vitro 3D endometrial co-culture system has been developed. The 
method is validated and has previously been demonstrated to structurally mimic endometrial 
tissue in vivo. When histologically evaluated under light microscopy, this 3D model has 
proven to mimic the in vivo endometrial structure, including a polarized epithelium with well 
developed inter-cellular junctions and stromal density similar to that seen in endometrial 
biopsies [170-172]. Further, immunostaining for the markers cytokeratin and vimentin in the 
3D construct have confirmed a monolayer of epithelial cells on the surface and stromal cells 
embedded in the 3D collagen matrix respectively, which was also observed with 
Hematoxylin-Eosin staining [56].  
This model has further proven to resemble in vivo conditions with regards to a relevant 
microenvironment and to mimic the receptive endometrium, including expression of 
progesterone regulated receptivity markers. Thus, the molecular profile of the in vitro 3D 
culture resembles receptive endometrium in vivo. The 3D endometrial construct has 
subsequently allowed for studies of the cellular and molecular events that occur during the 
first days of the human implantation process, including studies on markers of endometrial 
receptivity. It is now well established and has previously been used to study the impact of 
LNG and high dose mifepristone on human embryo implantation [56, 57, 173].  
2.13 PROGESTERONE AND PROGESTERONE RECEPTORS  
Steroid hormones derive from cholesterol in the biosynthetic pathway and have a common 
basic molecular four-ring structure made up from 17 carbon atoms. There are three groups of 
sex steroids depending on the total number of carbon atoms; estrogens (n=18), progestins 
(n=21) and androgens (n=19). Progesterone circulates in the blood bound to protein with a 
half-life of only a few minutes, metabolizes in the liver and metabolites are further excreted 
in the urine. When scientists in the 1950s replaced a methyl group with a hydrogen atom at 
position 19 on progesterone, it resulted in a more potent progestin, leading to the 
development of synthetic progestins [174].  
Steroid receptors all have a similar structure with a DNA-binding domain (C), a hinge 
domain (D) and a ligand-binding domain (E). The steroid receptors are transcription factors 
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that regulate gene transcription in a multistep process. When the steroid receptors are 
activated by their ligand, they form homodimers or heterodimers and recruit coregulators and 
thereafter bind the specific DNA sequences called steroid response elements. At binding, the 
complex induces or represses the transcription of downstream target genes [147]. The 
expression of steroid receptors in the human endometrium varies both spatially and 
temporally across the menstrual cycle [136]. 
 
 
Figure 8. Activation of the progesterone receptor (PR) by its ligand. PRE=progesterone response element. 
Modified from Chabbert-Buffet, Hum Reprod Update 2005. 
 
The genomic progesterone receptor (PR) belongs to the steroid receptor family and is a main 
regulator in the female reproductive tract. The PR is an intranuclear protein that specifically 
can bind progesterone and other progestins and through several steps induce transcriptional 
activity. Progesterone bind its receptor in the cytoplasm of cells, which causes a dimerization 
and conformational change that in addition attracts co-activators that bind and form a PR 
complex that subsequently translocates into the cell nucleus, binds the DNA and initiates 
transcription of the target gene. If a Progesterone agonist binds the receptor, co-activators are 
similarly bound and gene transcription is activated, whereas if an antagonist binds to the 
receptor, the induced conformational change will instead make it possible to co-repressors to 
bind, which will inhibit transcription. PR action takes minutes to hours. The human PR has 
two major isoforms; PR-A and PR-B and both isoforms bind to progesterone with identical 
affinity but with respective distinct functions in different cell types. They are structurally 
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alike although PR-B has an additional 164 amino acids in the N-terminal containing a third 
transcription domain, which PR-A lacks [62]. Both subtypes are expressed within the 
endometrium and are dramatically reduced in the epithelial cells during the secretory phase 
but persist in the upper functional zone of the endometrial stroma. PRA is the predominant 
type in the stroma during the secretory phase and early pregnancy, and the stromal cells near 
the uterine vasculature have the highest expression. Both the glands and stroma in the basal 
layer express PR throughout the cycle [175]. Progesterone receptor C (PRC) is another type 
of PR, which modulates the transcriptional activity of PRA and PRB [176]. High levels of 
PRC are expressed in the fundal region of the uterine myometrium during labor [177].  
There further exists a non-genomic, membrane bound PR in human tissue, which has 
predominantly been studied in the ovary, however also is expressed in intestines, smooth 
muscle, spermatozoa, breast cancer cells and in certain cells that lack nuclei such as red blood 
cells and platelets. The signaling from these non-genomic G-protein-coupled receptors 
(GPCR) is immediate and rapid by the activation of downstream second messengers. The 
membrane associated PRs (MAPR) are a group of four proteins, the most known being 
PGRMC1 [178]. 
 
Progesterone 
                                            
                    Mifepristone                                                          Ulipristal Acetate 
 
Figure 9. Molecular structure of Progesterone, Mifepristone and Ulipristal Acetate 
 
2.14 PROGESTERONE RECEPTOR MODULATORS  
Although belonging to the same class of compounds, different PRMs differ in activity on the 
PR, as well as in selectivity and potency of their metabolites and thus also in biological 
profile [179]. Differences in molecular structure of different PRMs influence their effect in 
the tissue. The relative proportion of co-regulators in different tissues will further determine 
PRM action and thus whether genes are being transcribed or downregulated [180]. PRMs 
bind both isoforms of PR with high affinity and can activate both co-activators and co-
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repressors, thus producing a mixed agonist-antagonist effect. Due to differences between 
different PRMs, they exert somewhat variable effects on the endometrium [181]. 
Mifepristone exerts a more antagonistic effect than UPA.  
Since PR signaling is essential for oocyte release at ovulation [182], it is not surprising that 
PRMs affect the follicular development and ovulation. PRMs have been shown to induce 
apoptosis in granulosa cells [183]. Both mifepristone and UPA further inhibit muscular 
contractions and ciliary beating frequency in the fallopian tubes [91]. 
Mifepristone, which is derived from 19-nortestosterone binds to the glucocorticoid receptor 
(GR) with high affinity and thus in addition to antagonistic effect on the PR elicits 
antiglucocorticoid activity. However low or single doses do not significantly affect cortisol 
levels [184]. UPA on the other hand is a derivate of 19-norprogesterone and in vitro studies 
show that UPA has less antiglucocorticoid activity than mifepristone, suggested to be due to 
decreased activity by their proximal supposed metabolites [179]. The antiproliferative effect 
of progestins on the endometrium is suggested to be due to upregulation of AR in the 
epithelium in presence of estrogen [185]. Mifepristone can also bind to the AR and further, 
mifepristone treatment increases the expression of AR in the endometrium [186]. AR 
expression is increased when progesterone levels drop and treatment with a PRM thus in line 
with this upregulates AR expression..  
2.15 PRM ASSOCIATED ENDOMETRIAL CHANGES  
The pharmacodynamic effects of PRMs are tissue- and species specific and vary depending 
on dose and duration of treatment, as well as presence of progesterone and PRs. A PRM 
alone can exhibit progestational, anti-proliferative and anti-estrogenic effects, while it has 
antagonistic properties in the presence of progesterone [62]. In the normal endometrium, the 
ratio of progesterone and estrogen, as well as their respective receptors determines histology. 
A prominent effect of long-term treatment with mifepristone or UPA is induction of 
amenorrhea and an increase in endometrial thickness detected by ultrasound. Since treatment 
with a PRM blocks the PR and the endometrium is left unopposed to estrogen, there are 
concerns that the described increased thickness is due to proliferative hyperplasia, perhaps 
with an intrinsic pre-malignant potential.  
PRM treatment can cause a spectrum of specific non-physiological endometrial changes. The 
appearances are similar with different PRMs and are thus considered a class effect [180, 187]. 
Endometrial pathology studies have histologically described the observed morphological 
features after PRM exposure, which have been coined PRM associated endometrial changes 
(PAEC). Glands in endometrium with PAEC can have varying appearance with discordant 
features and secretory activity, displaying admixed influence. The most prominent and 
distinctive trademark of PAEC is extensive dilated cystic glandular formations with watery 
content and inactive glands where the epithelial lining exhibits low mitotic activity and 
apoptosis. The characteristic features of PAEC are varying, also in accordance to the PRM 
used. Dilated cysts are believed to appear approximately to the same extent with UPA 
treatment as with mifepristone, however UPA generates more of non-physiological secretory 
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effects compared with mifepristone [187-189]. Further features include vascular changes with 
most often thin, however partially thick walls and compaction of the stromal compartment, 
which often is not decidualized [190]. The endometrium displaying PAEC does not fit into 
the histological classification of hyperplasia and neither to regular classification since the 
feature is neither proliferative nor secretory [187, 190, 191]. According to several reports and 
expert pathologists, the endometrial changes caused by PRMs are benign with no signs of 
atypia and have been demonstrated to be reversible after a few weeks to months after 
cessation of treatment [192-195]. A few studies that included analysis of proliferation 
markers in endometrium after PRM treatment report decreased levels of these markers [184, 
196]. 
2.15.1 PRMs for treatment of uterine leiomyoma 
Several clinical studies of PRMs for the treatment of leiomyomas have been published the 
last years and this approach has emerged as an attractive new therapeutic alternative to 
surgery. PRMs can inhibit cell proliferation and induce apoptosis in leiomyoma tissue, 
confirming the role of progesterone in development of uterine leiomyoma [184, 197]. Thus, 
both mifepristone and UPA effectively reduce the volume of leiomyomas and alleviate 
associated symptoms, with the prompt reduced bleeding in a majority of patients being an 
appreciated effect [184, 193, 194, 198-200]. However, due to the endometrial effects 
described previously, current recommendations include intermittent treatment during a 
limited time, with breaks between treatment periods for endometrial shedding. UPA in a dose 
of 5 mg daily is approved for use in clinical practice for treatment of leiomyomas and can 
safely be administered intermittently for long-term treatment. Each treatment period lasts 3 
months, with further shrinkage of leiomyoma with successive treatment periods.  
In a study by Donnez et al, 11% of the women displayed non-physiological endometrial 
changes similar to PAEC at screening without any pharmacological treatment, whereas 25% 
of women displayed PAEC 6 weeks after the 4th treatment course [195]. In previous studies, 
PAEC was reported in approximately 60% of women when the endometrial biopsy was taken 
at the end of a treatment period [193, 194]. The use of mifepristone for leiomyoma treatment 
has been studied in daily doses of 2.5-25 mg [184, 199, 201]. The lowest dose displayed 
relief of symptoms similar to higher doses, although the reduction of leiomyoma volume was 
smaller. No signs of PAEC were observed with the lowest dose, however study subjects 
discontinued treatment to a higher extent with this dose, which in addition also had been seen 
in a similar trial [200]. 
At the time when we started our studies, the morphology of PAEC had been described but 
there were no reports of underlying molecular basis or cell proliferation pathways to 
understand future implications of these changes.  
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3 AIMS OF THE THESIS 
 
The overall aim of the thesis was to explore the effects of PRMs UPA and mifepristone when 
used for emergency contraception and further developed for contraceptive purposes, in order 
to provide women with evidence-based information regarding mechanisms of action and 
implications of long-term use. Its main focus was on endometrial effects of these 
mechanisms, including possible impact on endometrial receptivity and embryo implantation 
after short-term treatment with UPA and low dose mifepristone as well as molecular 
exploration of PAEC after long-term treatment with mifepristone. Further, the possible 
interference of UPA used as EC on the ability of a regular COCP to achieve ovarian 
quiescence, when treatment is initiated immediately after UPA intake, was explored. 
 
The specific objectives of each study were: 
Study I 
Ø To compare the effects on ovarian activity when quickstarting a COCP after intake of 
UPA versus placebo. 
 
Ø To compare the effects on bleeding patterns and tolerability when quickstarting a 
COCP after intake of UPA versus placebo. 
Study II 
Ø To explore the effects of UPA on human embryo implantation process and known 
endometrial receptivity markers in an in vitro three-dimensional cell culture model. 
Study III 
Ø To explore the effects of two different low doses of mifepristone on known 
endometrial receptivity markers and human embryo implantation process in an in 
vitro three-dimensional endometrial cell culture model. 
Study IV 
Ø To characterize the differentially expressed genes and proteins in endometrium 
displaying PAEC compared with non-PAEC after long-term treatment with 
mifepristone. 
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4 MATERIALS AND METHODS 
The studies included in this thesis were conducted at the WHO collaborating center in the 
Department of Women’s and Children’s Health at Karolinska University Hospital in 
Stockholm, Sweden. Study I was a multicenter trial with three study sites and participants in 
addition from Dinox in Groningen, Netherlands and Chalmers Sexual Health Clinic in 
Edinburgh, Scotland. Embryos used in study II and III were superannuated and donated by 
couples for research purpose and obtained from the IVF clinic Fertilitetscentrum in 
Stockholm, Sweden. Methods used in the studies are diverse and include a randomized 
controlled trial (RCT) and explorative molecular laboratory studies. More detailed description 
of the materials and methods is provided in the original articles (Study I-III) and manuscript 
(Study IV). 
4.1 STUDY DESIGNS 
4.1.1 Overview of studies 
 
Table 1. Overview of study designs, methods and statistical analysis 
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4.2 STUDY SUBJECTS 
4.2.1 Study I 
Healthy, non-smoking women aged 18-35 years old with BMI < 30 kg/m2, regular menstrual 
cycles (25-35 days) and no contraindications to using COCP according to WHO Medical 
Eligibility Criteria (MEC) 1 or 2 and not at risk of pregnancy nor currently breastfeeding, 
were eligible for the study. Further, the physical and gynecological examination had to be 
normal at recruitment. Exclusion criteria included any contraindications to the study 
medications or use of an intrauterine device or progestogen-only method of contraception 
three months prior to study enrolment, or 12 months for the injectable progestogen method. 
However, current use of a COCP at enrolment was permitted since it was considered 
clinically relevant to describe the effect of treatment in relation to women who have missed 
several COCPs when seeking EC.  
4.2.2 Study II and III 
Endometrial biopsies were obtained from healthy, non-smoking volunteers between the age 
of 22 and 40, with regular menstrual cycles (25-35 days) and proven fertility with at least one 
spontaneous pregnancy previously. The women had not used any intrauterine or hormonal 
contraception within 3 months prior to the biopsy, were confirmed non-pregnant and further 
recommended to use a barrier method for contraception in the cycle that the biopsy was 
taken, if not sterilized (themselves or their partner if male). A routine gynecological 
examination was performed prior to inclusion. 
The blastocyst stage human embryos used in this study were donated by couples who 
previously had undergone in vitro fertilization (IVF) at the IVF clinic Fertilitetscentrum 
Stockholm in Sweden. The embryos were about to be discarded due to legislation as they had 
been either cryopreserved for 5 years or because the couple did not want to keep them stored 
at the IVF clinic any longer. The embryos were of good quality, suitable for transfer on 
thawing and graded by an experienced embryologist. 
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Table 2. Gardner and Schoolcraft’s blastocyst grading 
 
4.2.3 Study IV 
The endometrial biopsies used in this study were obtained from healthy, pre-menopausal 
women that had been treated with mifepristone during 3 months prior to surgical intervention 
due to symptomatic uterine leiomyoma in a randomized, placebo-controlled trial at 
Karolinska University Hospital, Stockholm, Sweden [184]. The women had not used any 
steroid hormonal compounds within 3 months prior to study start and were confirmed non-
pregnant. 
4.3 ETHICAL PERMITS AND CONSIDERATIONS 
All the studies were approved by the Regional Ethical Review Board, Karolinska Institutet, 
Stockholm, Sweden. Study I: Dnr 2012-123-31/1, clinical trial reg no NCT01569113, Study 
II and III: Dnr 00-134, Study IV: Dnr 02-410, clinical trial reg no NCT00579475. All 
studies were conducted in accordance with the revised ethical standards of the original 
Helsinki Declaration of 1975. The procedures in Study I and IV followed guidelines for 
Good Clinical Practice (GCP) and the studies were approved by the Swedish Medical 
Products Agency, Uppsala, Sweden. All participating subjects and couples that donated 
embryos were provided oral and written information and signed informed consent prior to 
participation. 
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Study I included treatment with a COCP and the volunteering women were thoroughly 
examined and reviewed regarding their medical history prior to inclusion. The most common 
side effects from this well known COCP are headache, nausea, breast tenderness and 
abdominal pain, however the risk of severe adverse events such as thrombosis from treatment 
were extremely low due to thorough screening and strict exclusion criteria. UPA is also a safe 
and well-studied compound, currently in use on the market. Participation in this study 
required several visits to the study centers during approximately 2 months, when at most 
intense this included transvaginal ultrasonography and blood testing 3 times per week. 
Since reproduction and the embryo implantation process significantly differ between species, 
the use of human endometrial cells and human embryos were considered necessary for Study 
II and III. The technique of collecting endometrial tissue is safe with few risks and is a 
standard procedure during gynecological examination. It can cause some discomfort and pain 
similar to insertion of an IUD but is of short duration and does not typically require 
anesthetics, although oral pain relievers were offered.  
The embryos donated for this study were generated through IVF and either donated by 
couples as they had decided not to store them further or the embryos had been stored for 5 
years and were supposed to be discarded as per Swedish legislation for storage of human 
embryos in IVF clinic. The embryos were handled by an experienced embryologist and 
cultured during 5 days, which falls well within national policy of permissible legal and 
regulatory duration for culturing human embryos in vitro 
(http://www.socialstyrelsen.se/barnochfamilj/graviditet/assisteradbefruktning) (accessed 
April 2017). 
Study participants and endometrial donors who volunteered for Study I-III were 
compensated economically for their contribution but participation was otherwise not 
obviously beneficial to the women and neither to the couples who donated embryos. 
Participants in Study IV had been referred to the hospital and were scheduled for surgery due 
to symptomatic uterine leiomyoma. Side effects from mifepristone treatment are well known 
and considered mild including nausea, headache, hot flushes and more seldom elevated liver 
transaminases. The women who were randomized to treatment with mifepristone rather 
benefited from participation as the treatment had positive effects on their symptoms, most 
prominently bleeding, and several of the women wished to continue treatment and not pursue 
with the planned surgical intervention at the end of study. 
All the blood- and urine samples in Study I were coded and sent to the laboratories as 
anonymous samples and endometrial biopsies and embryos used in Studies II-IV were also 
collected, coded and sent to the experimental laboratory as anonymous samples. 
4.4 METHODS STUDY I 
This was a multinational three-site, double-blind, randomized, placebo-controlled clinical 
trial conducted in Sweden, Scotland and the Netherlands. The women were randomized to 
receive either 30 mg of UPA (ellaOne®, Cenexi, France) or placebo when a lead follicle was 
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greater than 13 mm during a spontaneous cycle, followed by 21 consecutive days of COCP 
treatment. This follicle size was chosen as it corresponds to the mid- to late- follicular phase 
in the menstrual cycle, which is clinically relevant as EC intake at this stage possibly could 
delay the ovulation but a subsequent UPSI put the woman at risk of becoming pregnant if she 
would ovulate. During the pre-treatment period before randomization and inclusion, study 
visits were scheduled every 2-3 days for control of follicle growth, with a maximum of 6 
visits.  
4.4.1 UPA/placebo treatment and COCP period 
At inclusion, the study medication, (manufacturer of ellaOne® and placebo: Cenexi, France, 
packaged by: Créapharm, Le Haillan, France) was dispensed in a double-blind fashion and 
the subjects swallowed the tablet in front of the study staff. The COCP containing 30 µg EE 
and 150 µg LNG (Microgynon®, Bayer plc, Newbury, UK) was dispensed in an open-label 
fashion, given to the women in a box containing the blister with tablets. Instructions were to 
take one pill daily at approximately the same time each day, starting the day after UPA or 
placebo intake.  
During the COCP period, study visits continued every 2-3 days, where transvaginal 
ultrasonography and blood sampling for hormonal measurements were performed, producing 
a Hoogland score (Table 3), until the largest follicle was smaller than or equal to 13 mm, a 
maximum of 9 visits. When ovarian quiescence was reached (Hoogland score ≤ 3), study 
visits were reduced to once weekly. Some tablets from each blister were kept at the study site 
in sealed, marked envelopes for further drug accountability. The women made notes of tablet 
intake each day in their diary and were instructed to bring this and their box and blister to 
each scheduled visit during the study time. These were all further collected at the last visit. If 
sexually active with a male partner and not sterilized, the women were instructed not to rely 
on the COCP for contraception but to use condoms or abstain from sexual intercourse during 
participation in the trial. Condoms were handed out to study subjects throughout the study 
when applicable. The end of study visit was scheduled 9±2 days after the COCP period.  
4.4.2 Randomization 
An independent statistician produced a computer-generated randomization schedule. This 
schedule included a link between assigned treatment numbers and treatment codes and was 
securely stored by an independent contract research organization until locked for analysis. 
Sealed, sequential randomization envelopes corresponding to each treatment number were 
allocated and kept at respective site. 
4.4.3 Assessment of effect and safety 
4.4.3.1 Transvaginal Ultrasonography (TVU) 
Follicular growth and endometrial thickness were measured through TVUs at each study 
visit. The largest follicle in each ovary was measured in two axes and endometrial thickness 
measured at the thickest point between the anterior and the posterior uterine wall including 
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both endometrial layers. From the baseline visit at cycle day 5±1 after onset of menses, or 
withdrawal bleeding for COCP users, TVUs were performed 3 times every week during the 
pre-treatment period, until the size of the dominant follicle was larger than 13 mm. At this 
point, as earlier described, the woman was included and thus randomized to receive the UPA 
or placebo. During the following COCP period, TVUs were also performed 3 times weekly 
until the dominant follicle was smaller than or equal to 13 mm at two consecutive visits but at 
the weekly visits thereafter TVUs were not performed until again at the end-of-study visit. If 
an ovarian cyst larger than 30 mm persisted at this visit, subsequent TVUs were performed 
monthly until it resolved. 
4.4.3.2 Blood and urinary analysis 
Blood sampling for analysis of progesterone, estradiol and FSH was performed at the 
inclusion visit and at each study visit during the COCP period. A central laboratory in France, 
(CEMO, Choisy le Roi) conducted the blood analyses. The women were provided with tubes 
for daily urine samples, which were then brought back to the research site continuously, and 
stored at -20°C. These aliquots were used as backups, as analyses of pregnanediol 
glucuronide and oestrone glucuronide, the urinary metabolites of progesterone and estradiol, 
could be performed later on to assess ovarian activity in case of missing data on hormonal 
parameters or TVUs. A hospital-based laboratory in Scotland conducted the urinary analyses 
(RIE, Edinburgh, UK). 
4.4.3.3 Diary 
The study subjects were provided with a diary, in which they made daily records of vaginal 
bleeding and any adverse events occurring during the trial. Information about the bleeding 
episodes included duration and volume. Any untoward medical occurrence that a study 
subject might experience was considered an adverse event, although not necessarily with a 
causal relationship with the study treatment. 
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4.4.4 Hoogland score 
 
 
* 0.1 nmol/L ≈ 27 pg/ml 
Table 3. Grading of ovarian activity (Hoogland and Skouby 1993)  
 
The Hoogland Score is a method to measure the suppressive effect of a COCP on ovarian 
activity, described by Hoogland and Skouby 1993. Here, the stage of ovarian activity is 
assessed with measurements of endogenous hormone levels in blood and follicle size by 
ultrasonography [202]. Several investigators have previously used this scoring system in 
research studies where ovarian suppression was assessed during use of COCP [203-205]. 
4.4.5 Statistical analysis 
The hypothesis was that there would not be a significant difference in the number of women 
who would attain ovarian quiescence during COCP treatment in the UPA compared to the 
placebo group. Ovarian quiescence was considered as Hoogland score ≤ 3 and the assumption 
was that approximately 90 percent of women would reach this event. The study was designed 
as a non-inferiority trial, where the UPA arm was declared non-inferior to the placebo arm for 
the parameter percentage to attain ovarian quiescence. The non-inferiority margin was chosen 
at 20%, meaning that the difference between groups would not differ more than 20%, with an 
alpha risk of 2,5% (unilateral test). To test this hypothesis with sufficient power (80%), the 
sample size necessary was calculated to 72 subjects (36 women in each arm). In order to 
obtain this number, allowing for 10% dropouts, an estimated 80 subjects needed to be 
enrolled in the study.  
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In this study however, women were included and treated with the study medication with 
larger than anticipated leading follicles, which resulted in a larger than anticipated proportion 
of women who ovulated. The women who ovulated would never reach the primary efficacy 
criterion of attaining ovarian quiescence, but were instead doomed to be excluded in a non-
inferiority analysis, why this goal was not judged achievable. Since it was not feasible to 
rescue the original non-inferiority approach, the statistical plan had to be altered. Considering 
ovulation as a competing risk to attaining ovarian quiescence made it possible to apply a 
competing risk survival analysis of quiescence model. The analyses thus included estimating 
the cumulative incidence in the presence of competing risk events for both treatment arms. 
The covariates included were follicle size at inclusion, use of COCP in the previous cycle and 
cycle day at treatment. The full Analysis population (FAS) was analyzed, which included all 
participants that had been randomized and treated and with at least one available assessment 
of Hoogland score. Comparison of groups was performed using the chi-squared test (χ2) and 
the covariates were accounted for by the competing risk regression approach. The change in 
statistical plan was finalized before the database was unblinded and locked. 
4.5 METHODS STUDY II AND III 
In study II and III, the human embryo implantation process and markers of endometrial 
receptivity were studied after treatment with UPA and mifepristone respectively, using the 
3D human endometrial in vitro cell culture model which previously had been demonstrated to 
mimic in vivo endometrium [56, 57, 173]. The method included collection of endometrial 
tissue from proven fertile women, isolation of endometrial stromal and epithelial cells, 
construction of the 3D co-culture with the endometrial cells and allocating blastocyst stage 
human embryos to the cultures for further observation and analyses with and without 
treatment.  
4.5.1 Endometrial biopsies 
The participating study subjects determined the urinary LH peak by using a rapid self-test 
twice daily from menstrual cycle day 10 (Clearplan, Searle Unipath Ltd, Bedford, UK). 
Endometrial biopsies were collected on cycle day LH + 4. The tissue was obtained using a 
Pipelle aspirator (Cooper surgicals, USA or Prodimed, Neuilly-en-Thelle, France) from the 
upper part of the uterine cavity without local anaesthesia or prior dilatation of the cervix. The 
fresh biopsies were transported to the laboratory in sterile tubes containing fresh transport 
medium, Ham F-10, for further cell isolation processing. 
4.5.2 Endometrial cell isolation 
Isolation of endometrial stromal and epithelial cells was performed immediately after the 
biopsy was taken. The fresh biopsies were minced with a scalpel into very small pieces, 
approximately 1 x 1 mm and thereafter incubated with pancreatin-trypsin EDTA (0.05g/ml 
Trypsin-EDTA solution, Sigma-Aldrich, Stockholm, Sweden). A mixture of collagenase IV 
and DNAse (Worthington Biochemical, Lakewood, NJ, USA) was added and the supernatant 
removed after sedimentation. The treated cell mixture was washed with Ham F-10 and 
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thereafter filtered using a 40 micron mesh cell strainer (Falcon, BD Biosciences, Belgium), 
which allowed single stromal cells to pass through. The epithelial glands that were restrained 
in the filter were collected and treated with a collagenase III and DNAse mixture 
(Worthington Biochemical) and subsequently filtered through a 40 micron mesh cell strainer, 
yielding single epithelial cells. Stromal and epithelial cells were further preserved and stored 
separately in liquid nitrogen until used for the 3D endometrial co-culture. 
4.5.3 Embryos 
Embryos used in study II and III were all viable blastocyst stage human embryos of good 
quality, suitable for transfer. The standard method of embryo grading according to Gardner 
and Schoolcraft’s classification (Istanbul consensus 2011) was practiced and the embryos 
were graded between 3 and 4; AA/AB/BA by an experienced embryologist (Istanbul 
consensus 2011) (Table 2). The blastocysts derived from oocyte retrieval after ovarian 
stimulation, followed by standard IVF or intracytoplasmic sperm injection (ICSI) as per 
protocols of the IVF clinic. They had been individually cultured for 5 days; 2 days in droplets 
of G1 plus medium and under oil (Vitrolife, Gothenburg, Sweden) and then in blastocyst 
culture medium, G2 plus or CCM (Vitrolife) and thereafter vitrified on day 5 or 6, using 
RapidVit Blast (Vitrolife), placed in cryoloops and stored in liquid nitrogen. At thawing, the 
embryos were warmed in Thermoblast™Blast kit (Nidacon, Mölndal, Sweden) according to 
protocol and equilibrated in complete alpha medium for at least 2 hours, allowing them to 
expand, before they were transferred to the 3D cultures. The blastocysts that survived 
thawing and clinically met the quality standards for transfer were eligible for use in the 
studies. An embryologist handled the blastocysts during the thawing procedure and made 
quality assessment. 
4.5.4 Three-dimensional in vitro endometrial co-culture system 
The endometrial 3D co-cultures used in the studies were prepared, with only minor 
modifications, as described by Lalitkumar et al [173]. This was a modified and standardized 
version of the originally described model by Bentin-Ley et al [170, 206]. The collagen gel 
solution used, composed of bovine collagen solution Type I (Purecol 3 mg/ml, Advanced 
Biomatrix, San Diego, CA, USA), 10X PBS and NaOH with adjusted pH to 7.4, was first 
prepared and 175 µl of the mixture portioned at the bottom and lower sides of the Millicell 
cell culture inserts (EMD Millipore, Darmstadt, Germany), which were placed in a culture 
dish. Thereafter, the thawed stromal cells and 200µl of the collagen gel solution were mixed 
and added into the inserts. Each insert contained approximately 0.5-1.0 x 106 stromal cells/ml. 
After formation of the stromal gel, a thin layer of basement membrane matrix (Matrigel©, BD 
Biosciences, Belgium) was coated on top. Epithelial cells were mixed with modified alpha 
medium and seeded on top of the basement membrane coating, covering approximately 2/3 
of the surface, which would allow them to gradually spread and grow as a monolayer (Figure 
10). The modified alpha medium had been supplemented with 4 ml Amniomax C100, 5 ml 
fetal calf serum, 2000 IU penicillin-streptomycin and 0.2 ml L-glutamine (200 mmol/L) 
(Thermo Fisher Scientific, Waltham, MA, USA) and 0.5 g Bovine Serum Albumin (Sigma-
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Aldrich). Complete alpha medium, which had an final estrogen concentration of 0.3 nmol/L 
and progesterone concentration of 902 nmol/L and the endometrial 3D constructs were 
thereafter cultured for 5 days at 37°C in an incubator, with 5% CO2 in the air. The medium 
was changed every other day, when also the cultures were checked under a stereomicroscope 
(Zeiss, Oberkochen, Germany).  
 
Figure 10. 3D in vitro endometrial co-culture model  
 
4.5.5 PRM treatment 
After 3-5 days of culture or when the epithelial layer was confluent, the endometrial co-
cultures were treated with UPA or mifepristone in the treatment groups of respective study. In 
Study II, UPA in 5 µl of ethanol as vehicle (Medchem Express LLC, Princeton, NJ, USA) 
was added to 5 ml of media to reach a final concentration of 200 ng/ml (approx. 0.4 µM) 
[89], whereas in Study III, 5 µl of mifepristone (Sigma-Aldrich) in respective concentrations 
in ethanol as vehicle was added to 5 ml of media to obtain a final concentration of 0.05 or 0.5 
µM of mifepristone. The control group of cultures was exposed with media containing 5 µl of 
ethanol as vehicle/5 ml of media. The thawed blastocysts were randomly allocated to the 
different treatment groups and placed on the surface of the cultures on the same day as 
treatment, one per endometrial culture construct. They were thereafter cultured during 5 days 
until ultimately terminated. 
  47 
4.5.6 Assessment of embryo attachment and culture termination 
The cultures were examined for embryo under stereomicroscope (Zeiss) every other day 
when medium was changed. On day 5 of embryo-endometrial culture, the embryos were 
checked and tested for attachment by shaking the cultures mechanically and washing twice 
with phosphate buffered saline (PBS) and attachment rates were documented. The blastocysts 
were washed away if not attached. The 3D constructs were thereafter removed from inserts, 
the embryo portion dissected out and the remaining construct dissolved in 1 ml of Trizol 
reagent (Thermo Fisher Scientific) and stored at -80°C. 
4.5.7 RNA extraction and cDNA synthesis 
Total RNA was extracted from the Trizol dissolved 3D constructs using the Arcturus 
PicoPure RNA isolation kit (Thermo Fisher Scientific) as per the manufacturer’s protocol and 
the RNA concentration was measured using Nanodrop™1000 Spectrophotometer (Thermo 
Fisher Scientific). The samples were treated with DNAse in order to eliminate contaminating 
DNA. RNA integrity was determined using RNA 6000 Pico Labchip® and Bioanalyzer 2100 
Expert Software (Agilent Technologies, Santa Clara, CA, USA) was used to calculate the 
RNA Integrity Number (RIN) as per the manufacturer’s protocol.  
20 µl of first strand complementary DNA (cDNA) was synthesized from culture derived 
RNA using SuperScript VILO MasterMix (Thermo Fisher Scientific) and the Biorad 
Mycycler Thermal cycler was used for the thermal steps. A no template control and a reverse 
transcriptase negative control (RNase free water) were also prepared at the same time as 
controls in the real time polymerase chain reaction (PCR). 
4.5.8 Real-time PCR 
Real-time PCR analysis with quantification of mRNA levels was performed for PR and a 
number of genes of relevance for endometrial receptivity, decidualization and implantation (n 
= 17 in study II and n = 16 in study III) using Taqman primers (Thermo Fisher Scientific) 
(Table 4). 18S was chosen as the housekeeping reference gene on StepOne Plus instrument 
(Thermo Fisher Scientific) and amplification was performed in triplicates using Taqman 
Universal PCR MasterMix (Thermo Fisher Scientific) in a Microamp Fast Optical 96-well 
Reaction Plate (Thermo Fisher Scientific) with relative quantification (RQ) method. In 
accordance with the manufacturer’s protocol, the following thermal cycling conditions were 
performed: 2 min at 50°C, 10 min at 95°C and 40 cycles for 15 seconds at 95°C and for 1 min 
at 60°C. Real-time PCR data was collected using StepOne Plus software (Thermo Fisher 
Scientific) and further analyses were performed in Excel (Microsoft, Redmond, WA, USA). 
The results were analyzed by comparative threshold cycles (ΔΔCt) method, where Ct is the 
first cycle number at which the fluorescence passes the threshold of detection. The difference 
in expression levels between the groups was expressed in terms of fold change 2-ΔΔCt, as the 
product amount doubles every cycle.  
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4.5.9 Statistical Analysis 
Statistical analysis for the blastocyst attachment rate and real-time PCR data were performed 
using XLStat 2014 (AddinSoft SARL, Paris, France) and Graphpad Prism (Graphpad 
software, San Diego, CA, USA). Fisher’s exact test was used to calculate the difference in 
blastocyst attachment rate between the control and treatment groups. Based on the 
observations of real-time PCR data distribution and homogeneity of variance, either 
parametric Independent t-Test or non-parametric Mann-Whitney U Test was performed for 
intragroup analysis. The results were presented as mean ± standard deviation (SD) and a p-
value of < 0.05 was considered as statistically significant.  
4.6 METHODS STUDY IV 
Fourteen healthy, pre-menopausal women had been randomized to receive mifepristone 
during 3 months prior to surgical intervention of symptomatic uterine leiomyoma in a clinical 
placebo-controlled trial conducted at Karolinska University Hospital between November 
2004 and June 2007, investigating the impact of mifepristone treatment on uterine leiomyoma 
[184].  Endometrial biopsies obtained during surgery after the treatment period had been 
divided into two sections, one snap frozen and stored in liquid nitrogen and the other 
formalin-fixed, paraffin-embedded (FFPE), sectioned and stored at 4°C, awaiting further 
analyses. 
This study aimed at exploring the gene and protein expression in endometrium that displays 
PAEC in comparison with endometrium that does not have these non-physiological changes 
after three months of mifepristone treatment. Methods used included histological evaluation, 
microarray analysis, real-time PCR, protein extraction and further liquid chromatography and 
mass spectrometry. 
4.6.1 Mifepristone treatment 
Eligible women in the earlier published study were randomized to receive either 50 mg 
mifepristone, as one quarter of a 200 mg tablet Mifegyne® (Exelgyn, Paris, France), or an 
inactive comparator as one quarter of a B-vitamin tablet TrioBe® (Recip, Stockholm, 
Sweden) that visually looked identical, every other day during 3 months. Sixteen women had 
been randomized to placebo treatment and 14 women to treatment with mifepristone. 
4.6.2 Endometrial biopsies 
Endometrial biopsies were collected from the upper part of the uterine cavity with a 
Randall®curette (Stille, Stockholm, Sweden) without local anaesthesia or prior dilatation of 
the cervix. The biopsies used in this study were collected during surgery after 3 months of 
mifepristone treatment.  
4.6.3 Hematoxylin & Eoisin Staining and histological evaluation 
An experienced pathologist with expertise within endometrial pathology, blinded to treatment 
groups, had previously evaluated slides with Hematoxylin-Eosin stained endometrial samples 
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regarding occurrence of PAEC in the original study. The histological findings in the 
treatment group were reconfirmed with new Hematoxylin-Eosin staining of paraffin-
embedded sectioned endometrial samples (6µm thickness), after initial deparaffinization. 
First, the sections were stained for 1 minute in Hematoxylin (Vector Laboratories, Inc. 
Burlingame, CA, USA) and then destained in HCl-EtOH, followed by Eosin staining (Sigma-
Aldrich, St Louis, MO, USA) for 1 minute. Zeiss Axio Scope Microscope (Zeiss 
International) was used to image the sections, which subsequently were processed using 
Stereo Investigator Software (MBF Bioscience, Magdeburg, Germany). 
4.6.4 RNA extraction 
The endometrial tissue was homogenized in chambers at a shaking frequency of 30/second 
for 2 minutes with intermittent freezing in liquid nitrogen repetitively using a RetschTM tissue 
mill (Retsch KG, Haan, Germany). Total RNA was extracted using TRIzol (Invitrogen®, 
Thermo Fisher Scientific) and the RNA concentration was measured using Nanodrop™1000 
Spectrophotometer (Thermo Fisher Scientific). (All samples had an optical density 260/280 
ratio > 1.8) The samples were treated with DNAse in order to eliminate contaminating DNA. 
RNA integrity was determined using RNA 6000 Pico Labchip® and Bioanalyzer 2100 
Expert Software (Agilent Technologies) was used to calculate the RNA Integrity Number 
(RIN) as per the manufacturer’s protocol.  
4.6.5 Microarray 
100 ng of RNA per sample was labeled with biotin as per the protocol of SensationPlus™ 
FFPE Amplification and WT Labeling Kit (Affymetrix, Santa Clara, CA, USA). The labeled 
RNA was thereafter reverse transcribed to cDNA, which was further transcribed into labeled 
cRNA in vitro, and hybridized to GeneChip® Human Trancriptome Array 2.0 ST (HTA 2.0) 
(Affymetrix) at Bioinformatics and Expression Analysis core facility (Karolinska Institutet, 
Sweden). The raw data files of HTA 2.0 were processed using Affymetrix® Expression 
Console™ Software (Affymetrix) and estimation of gene signals through summarization was 
obtained with the algorithm iterative Probe Logarithmic Intensity Error Estimation 
(IterPLIER), with perfect match GC composition based background correction (PM-GCBG). 
Quantile sketch normalization was applied and further if probe sets were not annotated, they 
were discarded from analysis. In order to assess data quality including identifying outliers, 
hierarchal clustering, MA-plots and principal component analysis were produced using R 
software. Probe sets that had an expression intensity of < 40 in either of groups were removed 
for background correction. Analysis of the filtered data was then performed using 
Significance Analysis of Microarrays (SAM) in R software 
(https://github.com/MikeJSeo/SAM). The parameter fold-change was chosen at a minimum 
of two, either up- or downregulated for differentially regulated genes. 
The expressions of significant genes that were identified in microarray were reconfirmed by 
real-time PCR. 
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4.6.6 Real-time PCR 
Total RNA in equal amounts was reverse transcribed to cDNA in accordance with the 
protocol of Ovation® Pico WTA System V2 protocol (NuGEN Technologies Inc., San 
Carlos, CA, USA). Real-time PCR was performed on cDNA from 7 PAEC and 4 non-PAEC 
samples (as the 5th non-PAEC sample did not yield enough RNA) using the selected TaqMan 
gene primers and the TaqMan Gene Expression Assays and 7300 Real Time PCR System 
detection system (Thermo Fisher Scientific) as per manufacturer’s protocol. Nine target 
genes, identified by microarray analysis, were selected from the dataset and further analyzed 
with real-time PCR in order to determine the relative amount of each transcript in the two 
groups. 18S was chosen as the housekeeping reference gene as an endogenous control for 
data normalization and amplification was performed in triplicates using Taqman Universal 
PCR MasterMix (Life technologies, Thermo Fisher Scientific) in a Microamp Fast Optical 
96-well Reaction Plate (Applied Biosystems, Thermo Fisher Scientific) with relative 
quantification (RQ) method. The thermal cycling conditions were: 2 min at 50°C, 10 min at 
95°C and 40 cycles for 15 seconds at 95°C and for 1 min at 60°C. Real-time PCR data was 
collected using StepOne Plus software (Applied Biosystems, Thermo Fisher Scientific) and 
further analyses were performed in Excel (Microsoft, Redmond, WA, USA). The results were 
analyzed by comparative threshold cycles (ΔΔCt) method. The difference in expression levels 
between the groups was expressed in terms of fold change 2-ΔΔCt.  
4.6.7 Ingenuity Pathway Analysis  
The web-based software application and bioinformatics tool Ingenuity Pathway Analysis 
(IPA®, QIAGEN, Redwood City, CA, USA), (www.ingenuity.com) was used for 
performance analysis, integration and interpretation of microarray data. IPA gives access to 
its manually curated content of ingenuity knowledge base, which derives from sources like 
Entrez gene, Gene Ontology, GWAS, OMIM and RefSeq. In order to determine the major 
differences between the two groups regarding association with major canonical pathways, 
function and disease, the genes were uploaded into IPA, provided the change in expression 
profile was more than two-fold and that the genes were significantly differentially regulated. 
Additional filters for the functional analysis included only annotated genes and source of data 
only from human primary cells and tissues. 
4.6.8 Protein extraction 
Protein extraction from formalin-fixed paraffin-embedded endometrial sections from PAEC 
(n = 6) and non-PAEC (n = 6) and mass spectrometry including quantitative and qualitative 
data analysis were conducted at BMC and Science for Life Laboratory in Uppsala, Sweden.  
The first step of sample preparation included pooling of six tissue sections from each subject 
into one new sample. These samples were deparaffinized as previously described by [207], 
with minor modifications, and 20 µl of denaturation buffer thereafter added to each sample. 
The protein concentration was measured as per protocol using the Dot-it Spot-it® assay 
(http://dot-it-spot-it.com), with bovine serum albumin (BSA) as standard. The total volume 
was digested, unless the sample contained a higher protein concentration than 3.0 µg/mL, in 
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which case 71 ng of the protein amount was taken out for digestion. The proteins were further 
reduced, alkylated and in-solution digested with trypsin and resulting peptides thereafter 
purified using ZipTip® Pipette Tips (Merck Millipore, Darmstadt, Germany). After drying 
and resolving in 15 µL 0.1% formic acid, the peptides were subsequently separated in 
reversed-phase using the EASY-nLC II system (Thermo Fisher Scientific) according to 
protocol. 
4.6.9 Liquid Chromatography-Orbitrap Mass Spectrometry 
5 µL from each sample was placed on the pre-column EASY-Column, 2 cm, with inner 
diameter 100µm, 5 µm, C18-A1 and the peptides further eluted on the EASY-Column of 10 
cm with inner diameter 75 µm, 3 µm, C18-A2 (Thermo Fisher Scientific). The peptides were 
further separated using mobile phase A (Milli-Q water with 0.1% FA) and B (ACN with 
0.1% FA) at a flow rate of 250 nL/min with applied stepwise gradient from 2% of B up to 
100% of B during 90 min. Thereafter they were electrosprayed on-line to a Q Exactive™ 
Plus Mass Spectrometer (Thermo Finnigan, San Jose, CA, USA). The scan range of the 
survey scan was conducted between 400 Th and 1750 Th at a resolution of 70000 and 
fragmentation of the 10 most abundant peaks were performed with Higher-energy Collision 
Dissociation (HCD). The dynamic exclusion was set to 20s.  
A search in the database SWISS-PROT (EMBL-EBI, Cambridge, UK) against human 
proteins and file processing using the quantitative proteomics software MaxQuant version 
1.5.1.2 (Computational Systems Biochemistry, Martinsried, Germany) enabled protein 
identification and quantification. Search criteria for protein identification included at least 
two peptides matching, with 95% confidence level per protein. The false discovery rate 
(FDR) was estimated using a reverse database and a decoy database that included common 
contaminants. 
4.6.10 Statistical analysis 
Analysis of the filtered microarray data was performed using SAM in R software 
(https://github.com/MikeJSeo/SAM). Normalized data from microarray, real-time PCR and 
proteomic studies were subjected to either parametric Independent t Test or non-parametric 
Mann-Whitney U Test for intragroup analysis in order to find significance between groups. A 
p-value < 0.05 was considered as statistically significant. 
In IPA, the most significant canonical pathways were calculated based on the right tailed 
Fisher’s exact test, with a p-value < 0.05 considered significant. The generated p-value 
indicated the likelihood that the association between genes in our dataset and a given related 
pathway was due to random chance. A predicted activation or inhibition of a pathway was 
performed on IPA regulation Z-score algorithm (≤ 2 or ≥ 2 score). 
For the proteomic studies, proteins were included in the statistical analysis only if they had 
been identified in both sample categories and in at least two out of three samples in each 
category. Due to large variation in the number of proteins identified between samples, 
normalization was performed within each sample, with the obtained label-free quantification 
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(LFQ) intensities against the LFQ intensity for Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH). In the semi-quantitatively approach, proteins were reported as unique if detected 
in all samples from one category but not in any of samples in the other category. These 
proteins were considered upregulated in the group in which they were identified, however a 
fold change could not be calculated as those proteins were below detection limit in the other 
group. 
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5 RESULTS 
5.1 STUDY I 
5.1.1 Summary of main findings 
5.1.1.1 Study subjects and treatment allocation  
The study was conducted between March 2012 and August 2012. A total of 103 women were 
screened as potential participants at the three study sites and 76 women were enrolled in the 
study (Edinburgh, Scotland n = 18, Groningen, Netherlands n = 45, Stockholm, Sweden n = 
13) and received UPA (n = 39) or placebo (n = 37). There was no significant difference in 
demographic characteristics of the women in the two groups. 
All 76 subjects completed the study and were included in the FAS population. 5 subjects 
were excluded from the per protocol (PP) population due to 9 protocol deviations, all in the 
UPA group. These deviations included more than 3 days between visits before quiescence (n 
= 4), missed visits before outcome was reached (n = 2), intake of the first COCP on the same 
day as UPA (n = 2) and non-visualized dominant follicle at a visit (n = 1). Thus, 71 subjects 
were included in the PP population.  
5.1.1.2 Ovarian activity grades and cumulative proportions of quiescence and ovulation 
Among the 76 women treated, 47 (61.8%) reached ovarian quiescence (Hoogland score 1-3) 
and 25 (32.9%) ovulated (Hoogland score 6). There was no significant difference between the 
two groups in proportion of women reaching respective event (see Figure 2 and 3 in Paper I). 
The odds ratio (OR) for reaching ovarian quiescence or not did not significantly differ 
between UPA and placebo groups: 0.97 (95% CI: 0.39-2.46).  
By day 7 of the COCP period, 17 women (70.8%) in the UPA group and 14 (60.9%) in the 
placebo group had reached ovarian quiescence. All women had reached ovarian quiescence 
by day 14 of COCP intake. The patterns of cumulative proportions of women who ovulated 
were comparable between the groups. 10 out of 13 women in the UPA group had ovulated by 
day 6 and all women had done so by day 11. In the placebo group, all 12 women had 
ovulated by day 6. 
5.1.1.3 Factors influencing rate of quiescence or ovulation 
A significant covariate for ovarian quiescence proved to be follicular size at inclusion as 
quiescence occurred faster with smaller follicles at treatment (UPA or placebo), hazard ratio 
for follicle size 0.721 (95% CI: 0.569-0.913), p < 0.0066. All three women in the study who 
received treatment at a follicular size ≥ 18 mm ovulated, one in the placebo group and two in 
the UPA group. Cycle day at treatment or method of contraception in the cycle preceding 
study participation had no significant effect on proportions of women who reached ovarian 
quiescence or ovulated.  
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5.1.1.4 Safety  
Two women in the UPA group and one in the placebo group developed a luteinized 
unruptured follicle (LUF), and one woman in the placebo group a persistant asymptomatic 
follicular cyst of maximum diameter 44.5 mm, which had spontaneously resolved at a visit 
one month after end of treatment. 13 women altogether in the study reported unscheduled 
bleeding, with no difference in incidence between the two treatment groups. The most 
common adverse events that the study subjects experienced were headache, nausea, 
abdominal pain and nasopharyngitis. These were generally common although none 
considered serious, as 49 women reported at least one event during the course of the study 
(26 in the UPA group and 23 in the placebo group), however no woman discontinued the 
study due to an adverse event.  
5.2 STUDY II AND III 
5.2.1 Summary of main findings 
5.2.1.1 Embryo attachment  
The blastocyst stage embryos were randomly allocated to the different exposure groups; 
mifepristone 0.5 µM (n = 8), mifepristone 0.05 µM (n = 10), UPA 200 ng/ml (n = 10) and 
controls (n = 10). None of the blastocysts attached in the mifepristone 0.5 µM group whereas 
4/10 in the mifepristone 0.05 µM, 5/10 in the UPA 200 ng/ml and 7/10 in the control group 
attached to the 3D endometrial construct. There was no significant difference in blastocyst 
attachment rate between the UPA group compared to the control group (p = 0.650) and 
neither between the group exposed to mifepristone 0.05 µM compared to controls (p = 
0.370). In the mifepristone 0.5 µM group however there was a significant difference in 
attachment rate compared to the control group (p = 0.004). 
 
Figure 11. Blastocyst attachment rate in control and treatment group 
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5.2.1.2 Endometrial receptivity markers 
Genes belonging to different functional groups such as cytokines, decidualization factors, 
growth factors, integrins and transcription factors, which are of relevance to embryo 
implantation and endometrial receptivity, were selected for real-time PCR in Study II (n = 17) 
and Study III (n = 16), including mRNA for the PGR. The results are expressed as fold 
change (FC) between the treatment groups and the control group. All the cultures expressed 
PGR, although significantly downregulated in all treatment groups compared with the control 
group (Table 4). In Study II, 6 out of 17 genes were differentially expressed in the 
endometrial construct after UPA exposure compared to the control group; CALCR, FGF2, 
HAND2, OPN, HBEGF, IL6. Eleven out of 17 genes were thus not significantly altered with 
treatment. In the mifepristone groups in Study III, all genes were differentially regulated in 
the same direction at both concentrations of mifepristone in comparison with the control 
group. Nine out of the 16 studied genes were significantly altered in both mifepristone groups 
compared to controls and an additional three genes were significantly altered in only the 
group with the lowest mifepristone concentration (0.05 µM) in comparison with controls, 
namely IL6, IL1A and VEGFA. IL6 was the only gene that was significantly differentially 
expressed between the two different mifepristone groups (data not shown in table). 
 
* p-value < 0.05 
Table 4. Gene expression of receptivity markers studied by real-time PCR after exposure to UPA 200 ng/ml (≈ 
0.4µM), mifepristone 0.05µM and mifepristone 0.5µM, measured as difference in fold change (FC) compared 
with controls. 
 56 
5.3 STUDY IV 
5.3.1 Summary of main findings 
5.3.1.1 Endometrial histology 
Hematoxylin-Eosined stained slides with sectioned endometrial tissue were reassessed 
regarding occurrence of PAEC. In 7/13 (53.8%) of collected endometrial samples, a varying 
degree of non-physiological features corresponding to PAEC were observed among the 
PAEC samples. These changes were in line with the previous analysis by expert endometrial 
pathologist. Changes observed included both inactive and extensively apoptotic glands as 
well as secretory active, mitotic glands and cyst formations. In addition, atrophy and 
apoptotic degeneration was observed. Vascular changes included thin “chicken wire pattern” 
and ectatic vessels with thick walls (Figure 12). 
 
 
Figure 12. Hematoxylin-Eosin stained endometrial tissue following 3 months of mifepristone treatment showing 
non-physiological features agreeing with PAEC. Endometrial glands lined with single layers as well as 
incongruous, discordant epithelial type (A). Glands exhibit cyst formation and secretory activity (B). Chicken 
wire pattern (C) and thick-walled ectatic vessels (D). Glands further display apoptosis and accompanying 
apoptotic degeneration (E). 
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5.3.1.2 Microarray and IPA 
142 genes were upregulated and 39 genes downregulated by a minimum of two-fold in PAEC 
samples compared to non-PAEC. These 181 differentially regulated genes were uploaded 
into IPA for canonical pathway and network analysis. The predicted top five canonical 
pathways were corticotropin releasing hormone signaling, tight junction signaling, thyroid 
hormone metabolism I, protein kinase A signaling and cAMP mediated signaling. The five 
top associated molecular networks for genes in our dataset in the category diseases and 
disorders were connective tissue disorders, reproductive system diseases, organismal injury 
and abnormalities, cancer and immunological diseases. The predicted activation state was 
investigated for cancer diseases and none of the cancer related pathways were significantly 
activated or inhibited. 
5.3.1.3 Real-time PCR 
Nine genes relevant to functions and diseases of the uterus were selected from the dataset for 
real-time PCR analysis. Among these, three were significantly upregulated in endometrium 
with PAEC compared to non-PAEC endometrium; ADAM12 (p = 0.04), THY (p = 0.02) and 
TN-C (p = 0.04). The proliferation marker MKi67 was not statistically significantly altered 
(Figure 13).  
 
Figure 13. Tukey plots for significantly differentially regulated genes (THY1, ADAM12 and TN-C) 
 and proliferation marker MKi67 analyzed by real time PCR. * p<0.05 
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5.3.1.4 Mass Spectrometry-based Proteomics Analysis 
From the qualitative data analysis, three endometrial samples with the highest number of 
proteins identified in each group were selected for quantitative analysis. A total number of 
1772 proteins were identified across the six samples analyzed. Twenty-five proteins were 
upregulated and five downregulated in endometrium with PAEC compared with non-PAEC. 
Among them, 5 were significantly upregulated; TUBA4A (p=0.002), MYOF (p=0.006), 
TPM4 (0.013), RRBP1 (p=0.021) and DDOST (p=0.041) and 3 significantly downregulated; 
CSRP1 (p=0.001), DPYSL3 (p=0.012) and FMOD (p=0.045) at least two-fold in the PAEC 
group compared to the non-PAEC group. Twenty of the remaining 22 proteins were within 
detectable level only in endometrium with PAEC and two within detectable level only in non-
PAEC endometrium. These proteins are considered highly differentially regulated in 
respective group since below detection level in the comparison group, even though a fold 
change and p-value cannot be calculated.  
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6 METHODOLOGICAL CONSIDERATIONS 
The four experimental studies of the translational project that constitute this thesis comprise 
several methodological approaches. The different methods complement one another, all with 
aim at exploring different aspects of the effects of PRMs when used or to be developed for 
contraceptive purposes, including short-term impact on ovary and endometrium as EC and 
possible repercussion of long-term use on the endometrial tissue if used as regular 
contraception. Study I is a clinical randomized placebo-controlled multicenter trial and Study 
II-IV are exploratory molecular studies, each with individual weaknesses and strengths.  
 
6.1 STUDY I 
6.1.1 Strengths 
The main strength of the study is that it was as a double-blind, randomized, placebo-
controlled trial and as such provides the most compelling and highest level of evidence. 
Placebo was chosen as a control and the treatment was administered in a randomized manner 
in order to control for confounding factors and prevent bias from occurring, including strict 
inclusion criteria and thus avoiding systematic error. The effect of the COCP on ovarian 
activity was furthermore calculated by partially objective and subjective measures producing 
the validated Hoogland score. The double-blind randomization procedure reduced possible 
bias of the subjective measurement of follicle diameter to a minimum. The combination of 
EE and LNG used in the COCP studied is common worldwide and thus the findings in this 
study are also relevant to most country settings. 
6.1.2 Limitations 
The main limitation of this study is that the statistical analysis plan had to be changed due to 
the higher than expected proportion of women who ovulated.  
It was previously demonstrated in a study that initiation of a COCP when the leading follicle 
was 10 ±1 mm achieved ovarian quiescence in all study participants, whereas if the lead 
follicle size was 14 ±1 mm at initiation, 64% of them reached ovarian quiescence (Baerwald 
2006). Based on these results, the assumption for our study was that approximately 90% of 
women in the placebo group would attain ovarian quiescence during COCP treatment when 
this was initiated from follicle size > 13 mm. However, follicle size was measured at study 
visits every 2-3 days and not daily in our study, which rendered the lead follicle on average 
larger at intake of study medication than was expected at the planning stage.  
Pursuing the strategy of the initial non-inferiority analysis would result in exclusion of a large 
number of participants who ovulated, since they would never reach the primary efficacy 
criterion of attaining ovarian quiescence. Had not the statistical plan been changed, the results 
would have lost validity due to the substantial loss of statistical power with exclusion of 
many participants. It was therefore considered essential with a new appropriate statistical 
plan. Another limitation is that it was not possible to establish the exact day of ovulation due 
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to the 2-3 day intervals between study visits. On the other hand, error in accuracy of 
determining day of ovulation or ovarian quiescence rather postponed assessment, leading 
towards slightly overrating pregnancy risk if UPSI during COCP period, rendering the 
following interpretation and advice to women overly precautious. Moreover, ultrasonography 
measurements were performed at the three study sites by several investigators and an inter-
observer variability cannot be ruled out. However, this weakness was controlled for by the 
double-blind design. Within the RCT setting, study subjects recruited are often well 
motivated, comply to the treatment regime and are closely followed through regular visits. To 
what extent the setting and study subjects are representative of the target population for 
which treatment is addressed and results generalizable to a larger population, nationally or 
internationally and thus considered clinically relevant is  
Taken into account the strict inclusion - and exclusion criteria of such trials, this rather 
selected study population can limit the external validity of any RCT trial. However, in this 
case many exclusion criteria already apply when COCP treatment is initiated in settings other 
than a clinical trial, as use of WHOs MEC for contraceptive use is widely spread. The 
inclusion criteria of BMI < 30 in this study is probably the one parameter most likely to be 
renounced in the general setting. Population-based studies are needed in order to show that 
the impact of a treatment is true for a general population. Furthermore, the results from this 
study cannot be extrapolated to progestogen-only contraceptives or other methods of 
combined hormonal contraception. Neither does this study answer whether the COCP 
impacts the ability of UPA to postpone ovulation due to its study design. 
 
6.2 STUDY II AND III 
6.2.1 Strengths 
There are no good animal models to understand human endometrial receptivity and the 
process of human embryo implantation. The 3D in vitro endometrial co-culture system used 
in these studies does to a large extent mimic the receptive human endometrium in vivo. Fresh 
human endometrial cells are collected, isolated and immediately cryopreserved until used in 
the primary cell cultures, which is preferable to using indefinitely dividing continuous cell 
lines in order to more closely reflect the physiology of cells in vivo endometrium. The model 
has repeatedly proven to express a number of endometrial receptivity markers and to be a 
suitable system for studies of progesterone regulated factors. Its 3D structure provides a 
physiologically adequate space, which enables endometrial stromal and epithelial cells in the 
culture to interact and communicate in a natural paracrine and endocrine manner. In addition, 
it provides an invaluable tool for studies of early stages of human embryo implantation 
process, for which it was specifically developed. The model is reliable and reproducible and 
now well established for such studies. It can further be used to investigate various fertility 
regulating substances, as well as for studies of molecular signaling between the embryo and 
the receptive endometrial construct. 
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6.2.2 Limitations 
The 3D endometrial in vitro construct used in the studies contains both epithelial and stromal 
cells, which are the two main cells of the human endometrium. Although the co-culture 
model is complex, the endometrial tissue is far more so in vivo, with a high number of 
stromal and epithelial cells as well as other cell types, such as immune cells and endothelial 
cells, normally present in the cycling endometrium in a variable and dynamic manner. It is 
known that reciprocal interactions between all types of cells in the endometrium contribute to 
the endometrial milieu and formation of the transient receptive endometrium. Thus, further 
modifications of the model, incorporating other cell types and improving culture conditions 
could more accurately reflect in vivo endometrium. This would be a beneficial development 
of this model as a more in-depth understanding of the complex event of human embryo 
implantation and endometrial function could lead to improved contraceptive methods. 
Knowledge from such models further has the potential to enhance results from ART by 
developing therapies for women who suffer from infertility due to implantation failure. 
During the study process the 3D model had to be modified regarding number of stromal cells 
used in the cultures by decreasing the number of cells in the collagen matrix as initially the 
gel tended to contract. In addition, the model was further improved by using unicellular 
epithelial cells on top of the cell cultures as seen in endometrium, instead of initially used 
epithelial glands that easily grew as irregular clumps. 
Studies II and III are first time exploratory studies. Thus no power calculation based on 
previous study results could be performed. Research using advanced co-cultures with 
embryos and molecular studies with diverse techniques of exploring gene and protein 
expression in endometrial tissue and constructs is very resource intensive. Therefore, such 
studies are only possible to conduct in small scale. An important limitation of the 
implantation studies is the small number of cultures. This is due to the fact that human 
embryos are difficult to obtain for research purposes. The few number of cultures in our 
studies implies a risk of failing to demonstrate an effect of the PRM exposure, although one 
actually might be present, thus creating a false negative result. In statistical terms of 
hypothesis testing this represents a type II error. 
To test a series of graded PRM concentrations would be beneficial in order to more closely 
study the dose-response effect of these compounds. However, the limited availability of 
embryos restricts the number of cultures and by necessity also the number of different PRM 
concentrations possible to study. The concentration of UPA used in the treatment group (200 
ng/ml) was chosen to resemble the condition after UPA intake when used as oral EC, where a 
maximum mean serum concentration of 176 ± 89 ng/ml has been observed one hour after 
ingestion. Previous in vitro studies of UPA-EC have also used this concentration [89]. 
Regarding concentration of mifepristone, we chose to test two different low doses not 
previously studied regarding effect on embryo implantation or endometrial receptivity (0.5 
µM and 0.05 µM) in order to determine the dose-response. Another consideration regarding 
the in vitro culture compared to in vivo concerns the difference in metabolic drug clearance, 
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which is taken care of by liver enzymes such as cytochrome P450 enzyme 3A4 in vivo, 
however lacking in the in vitro construct.  
Analysis of the gene expression in our endometrial constructs gives information on the total 
expression emanating from the merged population of cells. If a technique to extract 
information regarding gene expression from individual cells in the endometrial construct 
were to be developed, such as laser capture micro-dissection (LCM) feasible in regular tissue, 
a detailed view of gene expression in compartments of each cell type could be performed. 
This would further deepen the knowledge of the substance studied as well as of dynamics 
within compartments during the endometrial implantation window. 
6.3 STUDY IV 
6.3.1 Strengths 
For best accuracy regarding diagnostics of PAEC occurrence, an experienced pathologist 
with expertise in endometrial pathology examined and evaluated the endometrial slides. The 
pathologist was blinded to treatment groups in order to minimize bias. Strengths of this study 
further include its study design with endometrial mifepristone-exposed samples originating 
from a randomized placebo-controlled trial and additionally the various methods used for 
molecular analysis of both gene and protein expression in these samples. A successful 
method to extract proteins from the FFPE endometrial samples has been standardized and 
described. This will hopefully inspire to further proteomic studies of endometrial tissue in the 
future, considering the presumed quantity of endometrial tissue stored worldwide in biobanks 
and may well contribute to new important discoveries. For the first time to our knowledge, a 
list of upregulated proteins in endometrium with PAEC is presented, providing a ground for 
future functional studies of proteins and potentially also for finding a valid biomarker for 
PAEC detection. In this study, we did not add endometrium from women who were not 
treated with mifepristone. The reason is that endometrium with mifepristone treatment loses 
its normal physiological stage and ends up in amenorrhea. This state of endometrium does 
not correspond to any of the phases of cycling endometrium of healthy women. Thus, the 
addition of such group will not provide us with any meaningful information in understanding 
the physiology of endometrium with PAEC.  
6.3.2 Limitations 
The main limitation of this study is the small sample size of the clinical trial, resulting in 
small comparison groups in the molecular studies of mifepristone-exposed endometrium. 
Another general limiting factor is that assessment of PAEC is subjective with currently no 
existing standard marker for the condition. This limitation was controlled for by the blinded 
fashion in which assessment was performed and further as just one expert pathologist 
performed the evaluation of endometrial samples in attempt to ascertain best possible 
accuracy. Although similarities of mifepristone with UPA, the results from this study cannot 
unreserved be extrapolated to UPA induced non-physiological changes. Further, all treated 
women in the study had symptomatic leiomyoma, which theoretically might influence the 
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endometrial response to mifepristone. On the other hand this condition is currently the most 
common indication for long-term PRM treatment and thus implications of the treatment 
indeed of particular importance to study in this specific group of women. Whether the results 
apply also to endometrium in non-affected uterus is indeterminate. Another possible 
limitation lies in the fact that the features of PAEC can vary substantially within the tissue 
and thus not be representative in the sample taken and/or differ between the different sections 
of the divided sample, rendering slightly uncorrelated results between morphology, gene 
expression and protein expression. In addition, the amount of endometrial tissue was 
insufficient to reconfirm protein quantification findings with Western Blot. The results from 
bioinformatics studies have to be confirmed in future experimental studies.  
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7 DISCUSSION 
7.1 SUMMARY OF MAIN FINDINGS AND POSSIBLE UNDERLYING 
MECHANISMS IN STUDY I 
We have explored the effects of UPA-EC on ovarian activity when quickstarting treatment 
with a common COCP after UPA intake in a double-blind, randomized, placebo-controlled 
trial. Our study demonstrates that UPA does not interfere with the ability of an ongoing 
COCP to induce ovarian quiescence when treatment is initiated immediately after EC intake. 
Quickstart treatment of COCP after UPA-EC intake is further safe and tolerable and does not 
increase the incidence of breakthrough bleeding. Quiescence was achieved after 7 days of 
COCP intake for most women, however could take up to 14 days for some (irrespective of 
UPA). No woman among them who ovulated did so after day 11 of COCP intake. The 
proportion of women who ovulated in the study was approximately 30%, similar in both 
groups, which can be explained by follicle size at inclusion.  
UPA binds the PR with high affinity but does not at the receptor site seem to interfere with 
the action of the subsequent daily dose of the progestin component LNG in the COCP 
studied. Although the contribution of EE in inhibition of ovulation is believed to be minor 
and EE alone requires much higher doses for a suppressive effect, a possible explanation for 
the maintained capacity of the COCP to induce ovarian quiescence might be that this effect is 
due to the component EE in the COCP, as it is undisturbed in exerting a suppressive effect on 
the hypothalamic pituitary ovarian axis (HPA) [208]. Another explanation is that although 
ovarian quiescence was studied, the trial was not designed to examine any impact of the 
COCP on the ability of UPA to delay ovulation. Following UPA-EC, the main effect to 
prevent fertilization seems to be a delay in ovulation rather than inhibition of ovulation [53]. 
The findings are consistent with previous reports of initiation of COCP at different follicular 
cycle stages where evidenced that the risk of ovulation increases with increased follicular size 
[209]. The reason for choosing a mid- to late-follicular phase in the ovarian cycle was the 
relevance to a clinical situation where a woman seeking EC would be in an obvious risk of 
unwanted pregnancy should further acts of UPSI take place and ovulation occur but where 
the ECP in addition could delay ovulation. However, as discussed in methodological 
considerations, due to the design where the women weren’t examined daily, treatment was 
given when the leading follicles were generally larger than had been anticipated and thus 
obstructed the initial statistical plan.  
7.2 THE RESULTS FROM STUDY I IN CONTEXT 
The results from our study cannot be extrapolated to other PRMs as the ECP, or to quickstart 
with a POP as the ongoing contraceptive method. Neither can a negative effect of the COCP 
on the ability of UPA to delay ovulation be excluded due to our study design where we did 
not have a group that received placebo instead of COCP after UPA.  
In a subsequent pharmacodynamic study by Brache et al, it was demonstrated that a POP 
containing the progestin desogestrel (DSG) initiated immediately after UPA-EC intake 
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significantly reduced the ovulation-delaying ability of UPA with 45% of women ovulating 
within 5 days after EC, compared to 3% among women only receiving the UPA-ECP. Similar 
to the results in our study using COCP as the ongoing contraceptive after EC, UPA did not 
have a negative effect on the ability of the POP to exert its contraceptive effect [210]. This 
information revealed that quickstart of a POP appears to counteract the main contraceptive 
effect of UPA, which is to delay ovulation beyond the life span of sperm. Therefore it is 
biologically plausible that quickstart of any progestin containing method after UPA-EC 
actually would mean that the intention to postpone a possible imminent ovulation and thereby 
prevent an unintended pregnancy with UPA could be jeopardized by the subsequent 
immediate start of a progestin containing oral contraceptive. Thus leaving the woman at the 
same risk of pregnancy as if she had not taken any contraceptives following UPSI. The study 
referred to is small in size, as is ours. However, based on these findings as well as findings in 
previous studies on interaction between PRMs and gestagens [211], it is not unlikely that this 
mechanism may apply broadly. 
7.3 SUMMARY OF MAIN FINDINGS AND POSSIBLE UNDERLYING 
MECHANISMS IN STUDY II AND III 
We investigated the effects of UPA and low doses of mifepristone on human embryo 
implantation and putative endometrial receptivity markers in a well-established 3D co-culture 
model. Although some of the endometrial receptivity markers in Study II were altered when 
exposed to UPA in an EC dose, most were unaffected. UPA did not significantly inhibit the 
early embryo implantation process, as there was no significant difference in attachment rate 
in the UPA group compared to controls. In study III, most receptivity markers were altered 
with the two different low concentrations, however they exerted functionally different effects 
on embryo implantation in a dose-dependent manner.  
The concentration 0.5µM effectively inhibited embryo implantation whereas a tenth of that 
concentration; 0.05µM did not affect the implantation rate significantly. Both concentrations 
however correspond to oral doses much lower than when used for EC [60, 81, 212-215]. 
Metabolic and pharmacokinetic studies after oral intake of mifepristone have demonstrated a 
linear kinetic relationship between single doses of 2-25 mg and increasing concentrations 
accordingly in serum. The higher of our concentrations chosen would roughly correspond to 
an oral dose of 5 mg. Should we further assume a linear relationship with doses below 1 mg, 
the lowest chosen concentration in our study would roughly correspond to 0.8 mg orally. 
Although without significant difference in our study, we observe that it seems to be a 
tendency towards less attachment to the construct even in the very low dose mifepristone 
group compared to the control group (40% vs 70%), which suggests a dose-dependent effect 
on the endometrium with mifepristone even at very low doses. On the other hand, the 
condition in vitro is different from in vivo tissue where the metabolic clearance of hormones 
occurs through the liver, whereas cultures in contrast are exposed in a continuous manner.  
The PRM binds to the PR with high affinity and thereby alter transcription of the factors 
regulated by progesterone. Although structurally similar, there seems to be differences in the 
 66 
action of mifepristone and UPA. Whether these are due to the difference in action on the PR, 
due to an antiglucocorticoid effect, are mainly dose dependent or depend on other factors 
remains to be explored. It is possible that mifepristone due to a more antagonistic profile has 
a more pronounced impact on altering studied endometrial receptivity markers compared to 
UPA. The dose-dependent difference in ability to attach to the mifepristone exposed 
constructs is believed due to effect on the endometrial construct and not to effect on embryo, 
as mifepristone in higher doses does not adversely affect embryo viability or its ability to 
implant [216]. 
7.4 THE RESULTS FROM STUDY II AND III IN CONTEXT 
Our studies confirm the findings from previous endometrial studies and clinical trials 
showing that PRMs exert a dose-dependent effect on the endometrium [72, 73, 75, 79, 85, 87, 
88, 217]. In a recent study by Lira-Albarrán et al, the gene expression in endometrium was 
explored through microarray after a single UPA-EC dose at mid-cycle compared to controls 
and further compared to ERA [218]. They concluded that UPA had an antiprogestational 
endometrial effect associated with a non-receptive endometrium and further that a key gene 
(PAEP) in trophoblast attachment was much downregulated in UPA treated endometrium. 
The post-ovulatory rise in progesterone was normal, however their results suggested that the 
decidualization process was affected. Contrastingly, the two well-known decidualization 
markers IGFBP-1 and PRL were not significantly altered by UPA in our study.  
Moreover and most importantly, our functional study of embryo implantation showed that the 
blastocyst in fact could attach to the UPA exposed endometrial construct, although some of 
the studied receptivity markers were altered. There seems to be a functional redundancy 
within the threshold of receptive endometrium, where the observed changes in levels of 
certain receptivity markers are counteracted by other compensatory mechanisms in a complex 
molecular interplay in order to enable successful implantation.  
There are obvious differences between in vitro and in vivo endometrial studies that can 
explain different findings in studies, apart from methodology used. The endometrial tissue in 
vivo is also influenced by factors from ovaries and from other cell types in the tissue, such as 
endothelial cells and leukocytes, which the in vitro system lacks.  
There is currently no reliable diagnostic tool for endometrial receptivity or valid single 
receptivity marker and studies on endometrial receptivity therefore importantly have to be 
interpreted with caution. Global gene expression studies report that PRMs can affect markers 
of endometrial receptivity at the molecular level [123, 219-221] but not all markers altered 
are associated with endometrial receptivity or relevant for embryo implantation. Recently it 
was shown that a single dose of mifepristone significantly altered the transcript profile in the 
endometrium of fertile women during WOI, however only 37% of the genes were associated 
with endometrial receptivity. They concluded that not all genes in the endometrium that 
change during transition from pre-receptive (LH+2) to receptive phase (LH+7) are regulated 
by progesterone [219].  
Low doses of mifepristone administered daily or weekly in humans do not affect ovulation 
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and fail to prevent pregnancy sufficiently although endometrial morphology and some of 
studied receptivity markers are affected [75, 79, 217]. Further, even well studied compounds 
such as LNG alter the gene expression in endometrium, although LNG does not adversely 
affect implantation [56, 57, 222, 223]. 
The results from our studies demonstrate the importance of functional evaluation of 
endometrial receptivity. The finding that the blastocysts could attach to the cultures exposed 
to UPA is in line with clinical trials of LNG- and UPA-EC. In a recent clinical study by Li et 
al it was further demonstrated that UPA intake before ovulation significantly prevented more 
pregnancies than when administered after ovulation compared to the number of expected 
pregnancies [92]. There is a marked increase in pregnancy risk for women who reported 
UPSI during days of highest probability of conception, as well as for those who had further 
acts of UPSI after ECP intake, regardless of method, which arguably indicates lack of 
significant postovulatory effects also for UPA [18, 59, 70, 102]. The observation of 
pregnancies in clinical trials after UPA intake thus supports the results in our in vitro study. 
The merged evidence is in line with the conclusion that the higher efficacy of UPA compared 
with LNG in clinical trials can be explained by the wider pre-ovulatory time window of effect 
of UPA, even after LH has started to rise when LNG has no effect [53, 71], and not through 
an anti-implantation effect.  
7.5  SUMMARY OF MAIN FINDINGS AND POSSIBLE UNDERLYING 
MECHANISMS IN STUDY IV  
We have characterized the altered expression of genes and proteins in endometrium 
displaying PAEC compared with non-PAEC after 3 months of mifepristone treatment in 
premenopausal women with uterine leiomyoma. The morphological features of PAEC 
samples observed coincided with previous descriptions and included disordered glands with 
variable degree of dilatation, lined with an incongruous epithelium as well as changes in 
vasculature and stroma. Three genes of relevance to function and diseases of the uterus were 
upregulated in endometrium with PAEC, as were 25 proteins, and 5 proteins were 
downregulated compared with non-PAEC endometrium.  
ADAM12, which was one of the upregulated genes in PAEC samples, is a member of a 
family of proteolytic enzymes with gelatinase activity, involved in cell-cell and cell-ECM 
interactions and involved in tissue remodeling [224]. Overexpression of the adhesion-
modulating glycoprotein TN-C has previously been observed in leiomyoma tissue [225], 
however we could not explain the upregulation in PAEC samples with correlation of 
submucosal location of leiomyoma in our study. The glycoprotein surface marker THY1 is 
involved in several cellular processes including wound healing and tumor suppression and of 
importance for fibroblast-ECM interactions. A decrease in the expression of THY1 is 
associated with malignant transformation in murine fibroblasts [226], however in our study it 
was upregulated in endometrium displaying PAEC compared to non-PAEC samples. The 
genes upregulated in our study are all associated with the cytokine transforming growth 
factor-β (TGF-β), and both TGF-β1 and TGF-β2 were upregulated in our study, however not 
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significantly or by two-fold or more respectively, which was some of the filters set in our 
microarray study. Mifepristone exposure has shown to increase levels of TGF-β in 
endometrium of Rhesus Monkey (Ghosh 1998) and possibly the mechanism by which the 
genes in our study were upregulated could involve TGF-β although this factor was not 
significantly increased here.  
The differentiated genes and proteins in this study are engaged in ECM, cytoskeletal 
organization and tissue architecture, indicating impact on endometrial morphology. The 
altered expression of these molecules may explain the specific histological features that 
constitute PAEC. None of the differentially regulated genes in our dataset were however 
involved in the endometrial cancer-signaling pathway based on IPA knowledge base.  
7.6 THE RESULTS FROM STUDY IV IN CONTEXT 
The frequency of PAEC in our study was 53.8%, which is in line with several previous 
reports from studies of mifepristone treatment of uterine leiomyoma [200, 227, 228]. Most 
studies examining the effect of mifepristone on uterine leiomyoma and additional 
endometrial impact have used a lower dose (2.5-10 mg daily), however the specific non-
physiological changes can be observed in the endometrium to a similar extent and sometimes 
to a higher extent than we report. In one study with the very low dose of 2.5 mg mifepristone 
daily, 86% of exposed endometrial samples displayed the characteristic features of large 
dilated cystic glands [192]. The non-physiological changes of PAEC do not increase with the 
number of treatment periods and are further reversible after discontinuation of treatment 
when the endometrium has been shed. Interestingly, PAEC can appear normally in 
endometrium that has not been exposed to a PRM, as diagnosed in approximately 10% of 
women in trials at screening [229]. 
Since development of PAEC during PRM treatment is a class effect of these compounds, the 
features are also seen in endometrium exposed to UPA and to a similar extent (≈ 60%). The 
features of dilated cyst formations have been observed in approximately 30% of UPA treated 
women [187, 229]. UPA in a daily dose of 5 mg for treatment of uterine leiomyoma has 
emerged as an attractive pre-operative treatment or therapeutic alternative to surgery, 
particularly important for women who wish to preserve their childbearing potential. Among 
women of reproductive age, uterine leiomyoma are the most common benign pelvic tumors, 
with a cumulative incidence of 70-80% at 50 years of age and a leading cause of 
hysterectomy worldwide [230]. In light of these facts, the implications of the commonly 
occurring features of PAEC during PRM treatment require in-depth exploration for 
evaluating the safety of long-term treatment. To our knowledge, when this study started, the 
molecular changes of PAEC had not previously been explored. 
Recently on the other hand, Whitaker et al published a study in which they examined the 
histological and molecular expression in endometrium after pre-operative UPA treatment of 
leiomyoma during 9-12 weeks [231]. They established that all the nine endometrial samples 
collected after UPA treatment displayed PAEC features and further compared them with the 
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molecular expression of proliferative and secretory phase endometrium collected from 
healthy women. Due to methodology, the rate of PAEC and the different PRMs studied, it is 
not possible to compare the two studies. In order to understand the molecular changes 
associated with PAEC after treatment with mifepristone, we instead chose to compare 
endometrium that displays PAEC with non-PAEC endometrium. Evidently, such study was 
not possible since all UPA treated samples had dilated cystic glands in the study by Whitaker 
et al. The comparison in their study was instead done between UPA treated women who had 
lost their normal endometrial cycle with healthy women having normal endometrial function, 
collected from different phases of the menstrual cycle. Further, one third of the women in 
their study reported spotting, which may interfere with the gene expression studies, whereas 
bleeding had ceased in all women within two weeks of mifepristone treatment in our study 
[184]. 
One of the most distinctive and appreciated effects of PRM treatment, apart from reducing 
the volume of the leiomyoma, is that endometrial bleeding is rapidly suppressed. The 
mechanisms for PRMs reducing bleeding effect are not known but seemingly frequency of 
amenorrhea increases with higher doses of PRM [184]. ADAM12 was upregulated in our 
study and it has previously been demonstrated that progesterone upregulates ADAMTS1 
whereas mifepristone inhibits the increase [232]. All of the samples in our study had been 
treated with mifepristone and thus gives the reason to speculate whether a more pronounced 
antiprogesterone effect, as in a higher mifepristone dose, would in fact reduce PAEC, as with 
bleeding.  
A question raised is further whether occurrence of PAEC simply is indicative of 
endometrium that for some reason has not been properly shed, since a significant minority of 
women has these non-physiological changes even without PRM treatment and since they 
disappear after cessation of treatment. Minor alterations in tissue hormonal levels could 
possibly add to the appearance. In our trial, mifepristone treatment decreased serum levels of 
estradiol and progesterone and there was a slight significant increase of free testosterone and 
androstenedione, although within the normal reference limit, compared with the control 
group [184]. Mifepristone is known to increase AR expression in the endometrium, which in 
addition may add to the mechanism of action by which it exerts its antiprogestational 
endometrial effect. 
PAEC has previously been classified as benign with no evidence of hyperplasia or atypia, 
which is in line with the findings in our study where no such changes were seen. 
Reassuringly, the endometrial cancer-signaling pathway was further not affected in our 
analysis as studied by IPA.  
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8 CONCLUSIONS 
 
Ø UPA when used for EC does not negatively affect the ability of a common COCP to 
induce ovarian quiescence when initiated after UPA intake.  
 
Ø Most women reach ovarian quiescence by day 7 of COCP treatment but some women 
do not reach quiescence until day 14 of COCP. 
 
Ø Exposure to UPA in a dose corresponding to the dose used for EC does not inhibit 
human embryo implantation process in vitro, though some of studied endometrial 
receptivity markers are significantly altered. 
 
Ø Exposure to a low concentration (0.5 µM) of mifepristone during the receptive period 
successfully inhibits human embryo implantation process in vitro. Mifepristone in 
low doses exert a dose-dependent effect on endometrial receptivity at the functional 
level. 
 
Ø The altered expression of molecules affecting ECM and tissue architecture in 
endometrium displaying PAEC demonstrated in this study may explain the specific 
non-physiological morphological features of PAEC. 
 
Ø None of the significantly differentially regulated genes in endometrium with PAEC 
are involved in the endometrial cancer-signaling pathway based on IPA knowledge 
base. 
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9 CLINICAL AND SCIENTIFIC IMPLICATIONS 
 
Based on the findings in study I, we concluded that quickstart of an ongoing COCP after 
intake of UPA-EC was safe and did not impair the COCPs effect on repressing ovarian 
activity. We pointed out however that the study was not designed to evaluate the possible 
impact that the COCP could have on the ability of UPA to exert is effect on delaying 
ovulation. After gathering evidence-based information from our trial as well as subsequent 
trials on the interaction of POP and UPA, EC guidelines have recently been changed. The 
current advice include to avoid quickstart of a regular contraception after UPA-EC intake and 
to delay initiation of hormonal contraception for at least 5 days after UPA. On the other hand, 
it is suggested in some guidelines that it may be more biologically correct to count the five 
days from the episode of UPSI rather than from UPA intake, as sperm after this time no 
longer can survive in the female reproductive tract 
(http://americansocietyforec.org/uploads/3/4/5/6/34568220/asec_fact_sheet-
_hormonal_contraception_after_ec.pdf) (accessed April 2017).  
In addition, women should not take UPA-EC within 7 days after use of progestin containing 
contraceptives, such as when women seek EC after UPSI when having missed pills from their 
regular POP or COCP. Further, a question raised from our study regarding whether or not the 
well-established advice of 7 days of COCP intake before it is reliable as contraception when 
initiated at mid-cycle or after LNG-EC really is sufficient, as it took up to 14 days to reach 
ovarian quiescence even for some women in the placebo group. 
From Study II and III new insights on the mechanism of action of mifepristone and UPA 
when used for EC has been presented. Exposure to UPA in a concentration corresponding to 
EC dose did not compromise the capability of the blastocyst stage embryo to attach to the 
endometrial construct in vitro. Women are withheld EC around the world due to the 
apprehension that UPA has postfertilizing effect and thus is to be regarded as a method of 
abortion. Our results are in line with the previously described mechanism of UPA to delay 
ovulation and thereby function as an EC when administered pre-ovulatory, not exhibiting anti 
implantation effect. We can thereby provide women with evidence-based information on 
UPA effect on human embryo implantation. Since UPA does not inhibit embryo implantation 
at the endometrial level, an unwanted pregnancy can occur if UPA was taken just before or at 
the time of ovulation. For an EC to be near perfect in preventing pregnancy after UPSI it is 
necessary for it to be effective during the whole cycle, postovulatory but before implantation, 
as is the case with the Cu-IUD.  
Interestingly, even a low concentration of mifepristone 0.5 µM, corresponding to 
approximately 5 mg orally, could effectively inhibit embryo implantation in our in vitro 
model, whereas a tenth of that concentration could not, displaying the known dose-dependent 
effect of mifepristone on the endometrium. Low doses of mifepristone had not previously 
been studied on the embryo implantation process, only a much higher concentration of 10 
µM, which also effectively inhibited implantation. From our results we conclude that low 
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dose mifepristone has great potential to be developed for contraceptive purposes, possibly as 
EC or on demand, which thus would provide a new type of contraceptive measure. 
Study IV generated information on the molecular profile of endometrium displaying PAEC 
after 3 months of mifepristone treatment due to symptomatic leiomyoma. In regards to the 
increasing use of PRMs for this indication, it is of great importance to closely evaluate the 
safety and understand the repercussions of this treatment, as the endometrial changes are 
prominent and commonly occurring. The results from this small study are reassuring as no 
molecules altered were involved in the endometrial cancer-signaling pathway, however 
mainly in the structural architecture of tissue, which may explain the morphological features 
of PAEC. A method of protein extraction from FFPE treated endometrial samples has been 
standardized and thus we present a list of proteins significantly altered in endometrium with 
PAEC, which could enable for future studies aiming to find a biomarker for detection of 
PAEC and further provides groundwork for studies on the functional role of altered proteins. 
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10 FUTURE PERSPECTIVES 
 
Insertion of a Cu-IUD is undoubtedly the most effective EC method and should be further 
promoted since underused and many remain unaware of this option. However, a Cu-IUD is 
not always suitable or available and thus the development of more effective methods for EC 
is clearly needed. Adding a COX-2 inhibitor to LNG-EC proved higher efficacy in 
postponing ovulation than LNG alone and future studies with this or similar compounds in 
combinations with different ECPs should be further explored. The advantage of a LNG based 
method is that LNG is widely available and doesn’t affect the efficacy of hormonal 
contraception in case of missed pills or quickstart of contraception after EC use.  
However, in order to address the wish of an ECP with efficacy in line with insertion of a Cu-
IUD, it is not enough to lean on methods solely affecting the ovulatory process, instead a 
more pronounced effect on endometrial receptivity is essential. An additional preventive 
effect after fertilization but before implantation is a determinant of near perfect prevention of 
unwanted pregnancy, since effectiveness of a method is closely correlated with its 
mechanism of action. New contraceptive strategies should therefore include manipulation of 
factors critical for endometrial receptivity in addition to affecting follicular development and 
ovulation. The most effective approach would address protection against pregnancy if further 
acts of UPSI occurred in the cycle, not risk interaction with hormonal contraceptive methods 
or be affected by body weight.  
An option to use contraception on demand would be a welcome contribution to the arsenal of 
possibilities in preventing unwanted pregnancy. Based on previous trials and observations 
from our studies, a PRM such as mifepristone has great potential to be developed for peri-
coital use. A suggestion would be to further study mifepristone in a single medium dose 
weekly or on demand (25-50 mg) and also in low daily short-term doses for EC following 
UPSI (for example 5 mg daily for 5 days). The suggested regimens are believed to affect the 
endometrium, making it non-receptive to the fertilized ovum, should UPSI have taken place 
during the fertile period and thus would increase effectiveness to ensure best possible 
prevention of unwanted pregnancy. Any such trial should include studies of bleeding patterns 
during and after the treatment as such disturbances might occur.   
PRMs like UPA and mifepristone further both have the potential to be developed as ongoing 
contraception. Studies for developing a daily pill or intrauterine method containing UPA are 
currently ongoing. The contribution of a PRM to the arsenal of contraceptive methods is 
believed to be an important and attractive option. When it comes to oral hormonal 
contraceptives, many women with contraindications to estrogen for medical reasons are 
confined to POP only if they do not wish to use an IUD or implant. The POP is not optional 
for some women due to bleeding irregularities and necessity of strict timing of pill intake and 
thus a new estrogen-free alternative would be most welcome. A PRM further could provide 
other added health benefits and appreciated side effects such as amenorrhea, thus a possible 
treatment for heavy menstrual bleeding (HMB) and related anemia. Of great importance to 
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follow through, should trials with PRMs as ongoing contraceptive methods be conducted, is 
the effect of the drug on breast, as mifepristone has been demonstrated to have an 
antiproliferative effect in breast cells [233] and thus speculatively PRM contraception have 
the added benefit of protection against breast cancer. Furthermore, trials are ongoing 
exploring PRMs for treatment of premenstrual syndrome (PMS). 
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11 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
11.1 BAKGRUND TILL STUDIERNA 
Osäkert utförda aborter bidrar stort till graviditetsrelaterad sjuklighet och dödlighet i världen 
och sker nästan uteslutande i låginkomstländer. Det uppskattas att var fjärde av de ca 213 
miljoner graviditeter som uppkommer årligen i världen avslutas med abort och att ungefär 
hälften av dessa är osäkert utförda. Under 2012 behandlades ca 7 miljoner kvinnor för 
abortrelaterade komplikationer på vårdinrättningar i låginkomstländer men mörkertalet i 
sjuklighet är förstås stort. Trots att en abort utförd i enlighet med WHO-riktlinjer är en väldigt 
säker medicinsk procedur med få komplikationer dör ungefär 23 000 kvinnor årligen i 
världen till följd av osäkert utförda aborter. De mest drabbade är de yngsta och fattigaste 
kvinnorna och fördelningen i världen är mycket ojämn med ca 62% av alla dödsfall i Afrika, 
söder om Sahara. Osäkra aborter har kallats ”The Preventable Pandemic”, den förebyggbara 
pandemin, eftersom sjuklighet och dödlighet till följd av dessa skulle gå att förebygga med 
tillgång till säkra aborter och aborteftervård inklusive legalisering och de-stigmatisering. 
Tillgång till moderna preventivmedel spelar också en avgörande roll. Utöver de reguljära 
preventivmetoder som finns har även akuta preventivmetoder utvecklats. 
Med en akut preventivmetod menas en metod att förebygga oönskad graviditet efter det att ett 
oskyddat samlag ägt rum men innan ett eventuellt befruktat ägg har implanterat i livmodern 
och en graviditet uppstått. Det kan vara aktuellt med akutpreventivmedel t ex vid misslyckad 
preventivmedelsanvändning som när en kondom spruckit, om flera av ordinarie p-piller 
missats eller efter våldtäkt. Den mest effektiva akuta preventivmetoden med närmare 100% 
effektivitet är insättande av en kopparspiral upp till 5 dagar (120 tim) efter att ett oskyddat 
samlag ägt rum (eller egentligen 5 dagar efter ägglossningen om den är känd). En fördel med 
denna metod är att den kan sitta kvar och skydda mot graviditet under flera år framöver som 
en reguljär preventivmetod. Verkningsmekanismen är dels toxisk effekt på spermier och ägg 
men spiralen gör också att livmoderslemhinnan (endometriet) inte blir mottaglig för ett 
befruktat ägg om det trots allt skulle ha lyckats komma till livmodern. Denna metod är säker 
och effektiv men förutsätter tillgänglighet till en vårdinrättning för insättande och passar 
kanske inte heller alla av andra anledningar.  
Det finns två dedikerade akut-p-piller på marknaden idag, dvs p-piller som förpackats och 
säljs i en styrka avsedd för akutprevention. Akut-p-piller har beräknats kunna förhindra ca 
75% av oönskade graviditeter men beror på när i menscykeln det oskyddade samlaget skedde 
och hur långt senare man tar tabletten bland annat. Det preparat som funnits längst och är 
mest spritt runtom i världen är levonorgestrel (LNG), ett syntetiskt gulkroppshormon 
(gestagen) som kan tas upp till 72 tim (-96 tim) efter samlag och som fungerar genom att 
skjuta fram ägglossningen så att spermierna inte kan befrukta ägget. Denna metod fungerar 
om den tas innan ägglossning men har ingen effekt precis innan eller under ägglossningen 
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och har heller inte någon effekt på endometriet, vilket medför att den inte skyddar mot 
oönskad graviditet under hela menscykeln.  
Det andra och senaste tillskottet till akut p-piller är en s.k progesteronreceptormodulator 
(PRM), ulipristalacetat (UPA) som har effekt upp till 120 tim efter oskyddat samlag. Den har 
också visat sig vara verksam genom att skjuta fram ägglossningen i minst 5 dagar vilket gör 
att spermier därför inte hinner befrukta ägget under sin livstid. UPA är något mer effektiv än 
LNG vilket beror på att den har ett något längre tidsfönster där den har effekt innan 
ägglossningen, och kan skjuta fram den även efter att hormonet LH börjat stiga då LNG inte 
längre har effekt. LH frisätts och når en toppnivå ca 36 tim innan ägglossningen och vid eller 
efter denna topp är båda preparaten verkningslösa. UPA utövar sin effekt i vävnaderna genom 
att binda till progesteronreceptorn (PR) där den kan ha både hämmande och delvis 
stimulerande effekt, varav namnet PRM.  
En annan typ av PRM är det först upptäckta anti-progesteronet mifepriston. Mifepriston har 
en något mer hämmande effekt på PR jämfört med UPA. Höga doser tillsammans med 
prostaglandin-analogen misoprostol (till exempel Cytotec) används för att medicinskt 
inducera abort. I låga doser fungerar mifepriston på samma vis som UPA, genom att skjuta 
fram ägglossningen och kan således fungera utmärkt som akut p-piller. Det är dock endast ett 
fåtal länder i världen där det är registrerat som akut p-piller pga politiska, religiösa och legala 
skäl eftersom den förknippas med abort, vilket också förmodas vara anledningen till att 
läkemedelsbolagen inte heller satsat på mifepriston för den indikationen. En del hävdar att 
anledningen till att UPA är mer effektivt än LNG är att det har effekt på embryots förmåga att 
fästa i endometriet samt att dess strukturella likhet med mifepriston gör att den fungerar som 
ett abortpiller, men effekten på endometriets mottaglighet för ett embryo eller dess förmåga 
att implantera i livmodern är inte tidigare studerat.  
Det är viktigt att ta reda på verkningsmekanismen för UPA när det används som 
akutpreventivmedel för att kunna tillhandahålla kvinnor evidensbaserad information. Om 
verkningsmekanismen inte visar sig vara att förhindra det befruktade ägget från att fästa i 
endometriet skulle acceptansen för det akuta preventivmedlet öka runtom i världen och 
därmed tillgången för kvinnor. Acceptansen för preventivmedel hänger ofta ihop med 
verkningsmekanismen där graviditet på vissa håll räknas från befruktningsögonblicket och 
inte som oftast då embryot implanterats i livmoderväggen. 
En daglig lågdosadministrering av PRM har potential att utvecklas till en reguljär 
preventivmetod och många kliniska studier har undersökt effekten av mifepriston i olika 
doseringar och behandlingsregimer för detta ändamål bland andra. I en 3-dimensionell 
provrörsmodell av mänskliga endometrieceller har effekten av en mycket hög 
mifepristonkoncentration visat sig hämma embryoimplantationen. Det är dock inte tidigare 
studerat hur låga doser av mifepriston påverkar endometriets mottaglighet för embryot eller 
dess förmåga att implantera i livmodern.  
För att kunna utveckla PRM som reguljärt preventivmedel eller som akut-p-piller med 
förstärkt effekt är det viktigt att undersöka effekten på endometriet i olika doser. 
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När en kvinna söker med behov av en akut preventivmetod är det ett gyllene tillfälle att 
erbjuda preventivmedelsrådgivning. Med tanke på att UPA skjuter upp ägglossningen kan ju 
behandlingen, även om den varit lyckosam vid det senaste oskyddade samlaget, leda till att 
ytterligare oskyddade samlag i samma menscykel ger oönskad graviditet då spermierna ju 
kan befrukta det ägg som lossas vid den uppskjutna ägglossningen. Studier visar att det är 
ökad risk att bli gravid vid fortsatta oskyddade samlag i samma cykel efter intag av akut p-
piller i jämförelse med att inte ha tagit tabletten. Det beror ju på att risken att bli gravid redan 
passerats för den som inte tog UPA eftersom de fick sin ägglossning som vanligt och fortsatta 
samlag efter äggets livslängd på ca 24 tim inte riskerar att leda till graviditet. Det är önskvärt 
att en effektiv reguljär preventivmetod påbörjas så snart som möjligt efter användande av 
akut-p-piller. Många kvinnor önskar påbörja p-pillerbehandling med vanliga kombinations-p-
piller innehållande östrogen och gestagen, eller tar dessa i vanliga fall men har missat flera 
piller och vill nu fortsätta med det. Eftersom UPA binder till PR riskerar den att konkurrera 
med gestagenet i kombinerade p-piller och därmed påverka deras hämning på 
äggstocksfunktionen. Av denna anledning har råden varit att då reguljär p-pillerbehandling 
påbörjas i direkt anslutning till intag av UPA, s.k ”quickstart”, skall en barriärmetod 
användas som skydd mot oönskad graviditet fram till nästa menstruation innan p-pillren 
säkert har effekt. En möjlig interaktion mellan UPA och kombinations-p-piller har inte 
tidigare studerats.  
För att kunna ge kvinnor evidensbaserad information om hur de på bästa sätt ska kunna 
skydda sig mot oönskad graviditet efter intag av akut p-piller är det viktigt att genomföra 
kliniska studier utformade för att undersöka detta. 
Både UPA och mifepriston har en dosberoende effekt på endometriet, där högre dos ger 
tydligare påverkan. Båda preparaten kan också användas för behandling av myom, godartade 
muskelknutor i livmodern, där behandlingen ges i låg daglig dos. Behandlingen brukar 
krympa myomen och framförallt göra att de vanligt förekommande rikliga blödningarna 
upphör eller minskar betydligt. Preparaten har dock visat sig ge en förtjockning av 
endometriet med förbryllande utseende i mikroskop inklusive vidgade sekretfyllda körtlar 
bland annat. Detta typiska utseende som uppstår hos ca 60% av de som behandlas med en 
PRM kallas för PRM associated endometrial changes (PAEC). PRM-behandlingen gör de 
flesta kvinnorna blödningsfria och eftersom endometriet då inte stöts bort, vilket normalt sker 
vid menstruation, föreligger viss oro att PAEC i förlängningen skulle kunna leda till sjukdom 
eller cancer i livmodern, även om några sådana tecken inte setts hittills. PAEC har visat sig 
vara reversibelt, dvs försvinner när behandlingen upphör och efter att endometriet stötts bort i 
en blödning. Det har inte gjorts några molekylära studier på endometrium med PAEC som 
kan förklara vad det rör sig om för förändringar, eller om cellulära signaleringsvägar i 
vävnaden är associerade med risken att utveckla livmodercancer vid långtidsbehandling. Det 
är viktigt att förstå betydelsen av PAEC och om det finns molekylära tecken på att tillståndet 
skulle kunna leda till cancer i livmodern. 
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11.2 STUDIE I 
I studie I ville vi undersöka hur äggstocken reagerar vid p-pilleranvändning som påbörjas 
direkt efter att kvinnan tagit UPA som akut p-piller, för att utröna om UPA försämrar den 
vanliga p-piller-effekten innan den gått ur kroppen. Studiens design skulle ge svar på om 
UPA påverkade äggstocken på ett annat sätt än sockerpiller (placebo). Den utfördes på 3 
centra i Europa. Vi rekryterade 76 friska kvinnor mellan 18-35 som lottades till att få UPA 
eller placebo innan de påbörjade regelbunden p-piller användning under 21 dagar. Vi 
studerade sedan hur äggstocken reagerade genom att undersöka kvinnorna med ultraljud 
regelbundet samt hormonnivåer i urin och i blod. Kvinnorna fick också fylla i en dagbok där 
de skrev ner biverkningar och blödningsmönster. Totalt fick 39 kvinnor UPA och 37 fick 
placebo. Vi kunde visa att det inte fanns någon skillnad mellan hur äggstocken reagerade på 
p-pillren beroende på om kvinnan fått UPA eller placebo. Den viktigaste faktorn som 
avgjorde om kvinnorna fick ägglossning trots att de påbörjade p-pilleranvändning var hur stor 
äggblåsan var när de tog UPA eller placebopreparatet. Med anledning av vår studie (och 
sedan efterföljande studier) har riktlinjer för hur quickstart av reguljär preventivmetod efter 
akut p-piller ändrats. 
11.3 STUDIE II OCH III 
I studie II och III studerades effekten av PRM på endometriet och på förmågan hos det 
befruktade ägget att fästa till en tre-dimensionell provrörsmodell av endometriet. Dessa 
studier var experimentella till sin natur. Modellen bestod av celler som kom från en enkel 
provtagning där vi tog ut en liten del av endometriet från frivilliga friska kvinnor i fertil ålder 
strax innan den tidpunkt i menscykeln när kvinnan normalt sett kan bli med barn och 
isolerade och blandade sedan cellerna med kollagenlösning och byggde 3D modellen som 
efterliknar hur endometriet ser ut i verkliga livet. Befruktade ägg som bevarats i frys i 5 år 
och som enligt lag skulle kastas donerades från par som genomgått IVF-behandling 
(provrörsbefruktning). Vi studerade andelen av embryon som fäste till endometriemodellen 
efter att den behandlats med UPA (studie II) och två olika låga koncentrationer av 
mifepristone (studie III) och jämförde med en kontrollgrupp som inte fått någon PRM-
behandling. Vi studerade även hur olika gener av betydelse för endometriets mottaglighet för 
det befruktade ägget uttrycktes i 3D-modellen. Man kunde inte se någon signifikant skillnad i 
hur många befruktade ägg som fäste mellan UPA och kontrollgruppen men med den högsta 
mifepristonkoncentrationen sågs en signifikant skillnad där inte några ägg lyckades fästa till 
endometriemodellen, vilket de kunde vid den lägre av koncentrationerna. UPA påverkade 
uttrycket av vissa av de studerade generna men flertalet var opåverkade medan båda 
mifepristonkoncentrationerna tydligt påverkade genuttrycken i en likartad riktning trots 
funktionellt så olika resultat när det gällde embryots förmåga att fästa vid 
endometriemodellen. Exakt vilken betydelse detta har i praktiken är osäkert i nuläget men 
tänkbart är att även låga doser dagligen under några dagar efter oskyddat samlag skulle kunna 
användas som en akutpreventivmetod, möjligen att utvecklas ”on-demand”, alltså att ta precis 
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inför el strax efter samlag. Studien är viktig för att demonstrera att den huvudsakliga 
verkningsmekanismen av UPA som akut p-piller inte är att påverka embryoimplantationen 
utan att förhindra att ägget befruktas genom att skjuta upp ägglossningen vilket tidigare 
visats. 
11.4 STUDIE IV 
I studie IV undersökte vi gener och proteiner i endometrium från kvinnor som lottats till 3 
månaders behandling med mifepriston pga symtomgivande myom som skulle opereras bort. 
Endometrium från 13 kvinnor samlades ihop vid operationerna, varav 7 hade PAEC och 6 var 
utan dessa förändringar (non-PAEC). Vi jämförde uttrycken av gener och proteiner i de båda 
grupperna med olika avancerade tekniker samt analysprogram för att studera vilka 
signalvägar och processer som de förändrade molekylerna är involverade i. Studien visade att 
det var ökat uttryck av 142 gener och minskat uttryck av 39 gener i PAEC-gruppen jämfört 
med non-PAEC. Dessa analyserades sedan vidare med Ingenuity Pathway Analysis där det 
inte sågs någon påverkan på processer som är involverade i utveckling av livmodercancer. 
Det var ett ökat uttryck av 25 proteiner och ett minskat uttryck av 5 proteiner i PAEC-
gruppen och vi noterade att de molekyler som påverkats av mifepristonbehandlingen är av 
vikt för vävnadens strukturella uppbyggnad, vilket kan förklara den typiska bild som ses vid 
mikroskopisk undersökning av PAEC. Denna studie underbygger resultat som visar att PAEC 
inte leder till cancer. 
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